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Abstract 
Tumor Necrosis Factor-alpha (TNF-a) has long been used in cancer treatment, but 
due to its severe side effects, and the development of resistance and insensitivity of tumor 
cells, the use ofTNF-a in treating cancer patients is limited. With the aim to potentiate the 
antitumor effect of TNF-a and reduce the dosage used as well as the side effects, 
combination treatment with hyperthermia is then developed. Two types of hyperthermia 
treatments have been proposed: fixed-temperature hyperthermia and step-down 
hyperthermia. The latter means heating the tumor cells at a high temperature for a short 
period oftime and then at a low temperature for a long period of time. Both were claimed 
to be able to enhance the cytotoxic effect of TNF-a and very effective against both TNF-
sensitive and resistant tumor cells. Their effectiveness，as well as their harmful effect on 
normal cells, are yet to be compared in both in vitro and in vivo models. In addition, 
sequence of treatment is known to be very important to these treatments. Inappropriate 
TNF administration time will lead to vanishing of synergism, or even elimination of effect; 
therefore it is very important to find out the optimal TNF administration time. The 
mechanism ofhow the two individual treatments cooperate has to be investigated. 
In the present study, murine Ehrlich Ascitic Tumor ^ A T ) and human leukemia HL-
60 cells were used in the investigation of these combined treatments. In the in vitro 
experiments for determining treatment sequence, administration ofTNF-a 4-6 hours before 
heat treatment was found to be the optimal sequence of treatments. Adding TNF-a after 
heat resulted in either loss of enhancement of efFect, or even protective effect of heat 
against TNF cytostaticity and/or cytotoxicity. For both EAT and HL-60 cells, combined 
treatment with TNF-a and 3-hour fixed-temperature hyperthermia at 43°C was the most 
effective treatment. Synergism was also observed between TNF-a and fixed-temperature 
hyperthermia, and apoptosis was found to be induced. Although higher growth and viability 
were obtained after combined treatment with TNF-a and step-down hyperthermia with 1 
hour at 43°C and 24 hours at 40°C, this treatment was also effective; however, most ofthe 
effect was found to be contributed by the step with long-duration heating. When the 
heating duration was limited to 3 hours, the treatment was found to be less effective. 
Moreover, growth suppression effect of these treatments was found to start earlier than the 
cytotoxic effect. Effects of TNF + fixed-temperature hyperthermia and TNF + step-down 
hyperthermia with long heating duration were found to last for a long period of time, but 
that ofTNF + step-down hyperthermia with short heating period was found to last for just a 
short period of time. 
Combined treatment with TNF-a and hyperthermia was found to be harmless to the 
Human Coronary Artery Endothelial Cell unless the cells were exposed to heat for a 
prolonged period of time. Combined treatment with TNF-a and step-down hyperthermia 
with 1 hour at 43�C and 24 hours at 40°C was thus undesirable. 
TNF + fixed-temperature hyperthermia was found to decrease GO/Gl-phase cells 
while increasing S-phase cells. This effect was especially strong when TNF-a was applied 
to cells 3-4 hours before heat. TNF-a alone was also found to stimulate the cells to go to S 
phase without killing them, and the stimulation peaked at 3'^  and 4^ hour ofincubation with 
TNF-a. The result suggested that TNF-a might have sensitized the cells to heat by 
stimulating the cells to enter S phase, at which stage, the cells were killed by heat. 
Result from in vivo study was consistent with the in vitro study. TNF + fixed-
temperature hyperthermia was found to be the most effective treatment and synergism 
between TNF-a and hyperthermia was also observed. The treatment was found ineffective 
when the sequence of treatment was reversed. Protection by heat against TNF-a was 
suggested from the result. 
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Chapter One: Introduction 
1.1 Tumor Necrosis Factor-a in Cancer Treatment: 
1.1.1 Historical Background: 
Tumor Necrosis Factor-alpha (TNF-a) has long been used in cancer treatment in 
history. Its use was stimulated by the observation that certain cancer patients who 
developed concurrent bacterial infections also experienced remissions of their malignant 
disease in 1700s (Bemadette and Stames, 1994). However, not until the next century was 
this treatment used to tackle malignant disease. In 1868, Busch first tried to treat sarcoma 
by transmission of erysipelas. In 1891-1936, the first large scale attempt to treat sarcoma 
by injection of a mixture containing gram-positive organism, heat-killed Streptococcus plus 
gram-negative organism, and heat-killed Serratia marcescens was done by William B. 
Coley. This mixture was later called the Coley's toxin. In 1975, Carswell and his 
colleagues found out that the serum from mice infected with Bacillus Calmette Guerin 
(BCG) and subsequently treated with endotoxin contained a substance capable of inducing 
tumor necrosis in certain transplantable tumor in mice, and they named it Tumor Necrosis 
Factor (Permica et. al., 1987). Purified TNF-a from natural sources was used in pre-
clinical and clinical studies of TNF treatment, but the presence of endotoxin and other 
biologically active molecules in those preparations limited their uses. In 1984，the first 
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TNF-a cDNA was cloned OPennica et. al., 1984). In 1985, using the recombinant DNA 
methodology, large quantities of highly purified (>99%) recombinant human TNF-a were 
produced for pre-cIinical and clinical use (Aggarwel et. aI., 1985). 
1.1.2 Mechanisms ofAction: 
TNF-a carries out its anti-tumor activities by firstly binding to the TNF receptors, 
R55 and R75. Different cells express these receptors at different densities, and this 
difference may lead to different responses of the cells to TNF-a ^Iohmann et. a/.，1989). 
Bound TNF receptors will cluster and will be internalized (Yamagishi et. al, 1990). 
Association of the internalized TNF complex with G protein will provide a signal 
transduction coupling mechanism for TNF-a to carry out its cytotoxicity. The anti-tumor 
actions ofTNF-a are via a number ofpathways. 
1.1.2.1 Production ofReactive Oxidative Species: 
TNF-a was found to carried out its cytotoxic effect partly through the production of 
reactive oxidative species, such as superoxide radicals (O2"), hydrogen peroxide and 
hydroxyl radical. The addition of antioxidant or iron chelator inhibited TNF cytotoxicity 
(Schulze-OsthofFe/. al, 1992). The mitochondrial electron transport system involves four 
components ^"ig. 1.1). Complex I involves NADH dehydrogenase, complex II involves 
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Fig. 1.1 Mitochondrial Electron Transport System and the Production of Reactive 
Oxidative Species Induced by TNF Treatment. 
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complex IV involves cytochrome a. The third complex is believed to be the target of TNF-
oc. Electron flow at complex HI is blocked by TNF-a and the electron is then transferred to 
oxygen, which acts as an electron acceptor, and thus form superoxide radical. Schulze-
OsthofF and his colleagues (1992) found out that inhibition of cytochrome c reductase by 
antimycin A potentiated TNF-mediated injury, but if electron flow to ubiquinone was 
blocked at complex I or II，the cells would be protected; and inhibition of complex IV had 
no effect on TNF-a cytotoxicity. The free radical hence produced would damage the DNA, 
proteins and lipids of the tumor cells. 
1.1.2.2 Increase ofIntracellular Free Calcium Concentration: 
According to Kong et. al. (1997), TNF-a can increase Ca^ ^ uptake, as well as 
intranuclear and cytosolic Ca^ .^ When the Ca^ ^ channel was inhibited, TNF cytotoxicity 
against L929 cells would also be lowered. TNF-a activates phospholipase C (J*LC). PLC 
catalyzes the conversion of phosphatidylinositol to inositol triphosphate which stimulates 
Ca2+ release ^"ier et. al,, 1993)，and the uncontrolled increase in free Ca:+ concentration in 
cells leads to cell death. 
1.1.2.3 Activation of Ca^^Mg^^-dependent Endonuclease: 
Another mechanism closely related to the increased influx of Ca?+ is the activation of 
Ca2VMg2+-dependent endonuclease. Activation of this enzyme by TNF-a is involved in 
apoptosis (Woo et. al., 1996). TNF-induced apoptosis was also found to be related to the 
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increase of intranuclear Ca^ ^ by Bellomo et. al (1992), and can be inhibited by protein 
kinase C ^*KC). Induction of apoptosis by TNF-a also involves the activation ofhydrolysis 
of sphingomycin to ceramide (Cai et. al., 1997; Kim et. al, 1991; Dressier et. a!., 1992; 
Jarvis et. al., 1990; Kolesnick and Golde, 1994). Bcl-2 gene, which inhibits several forms 
of apoptosis, can also be suppressed by TNF-a (Chen et. al, 1995). These actions of 
TNF-a empower TNF-a itself to induce apoptosis in tumor cells. 
1.1.2.4 Decrease of glucose uptake and Protein Svnthesis: 
Tumor cells require higher amount of energy for growth than normal cells and thus 
glucose transport is very important for tumor cells. Glucose uptake is decreased by TNF-a 
and protein synthesis is also slowed down (Fung et. al., 1985), which would in tum slow 
down cell growth. TNF-a was later found to decrease glucose transporters density on cell 
surface and reduce transporters' affinity for substrates (Fung et. al., 1995). Cell death may 
be contributed by deprivation ofenergy. 
1.1.2.5 Formation ofIon-permeable Channel: 
Kagan and his colleagues (1992) found out that TNF-a could act as ion channel. 
They discovered that addition of TNF-a to human U937 histiocytic lymphoma cells 
increased ^^a^ uptake by 100%. The ion-permeable channel formed by insertion ofTNF-a 
onto the membrane works best at acidic pH, and is basically permeable to either charge 
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ions; but have a preference of cation over anion. TNF-a can thus increase cellular Na+ at 
acidic pH. 
1.1.2.6 Activation ofPhospholipase: 
One ofthe signaling pathways ofTNF-a involves the activation of phospholipase A2 
(pLA2). Release of arachidonic acid from phospholipid is resulted from PLA2 activation, 
and is correlated to TNF cytotoxicity (Suffys et. aL, 1991). Phospholipase D is also 
activated by TNF-a and cytolysis is preceded by the activation (De Valch et. al., 1993). 
1 • 12.1 Increase of S-phase Cells: 
Distribution of cells at different cell cycle phases can be shifted under the influence 
ofTNF-a. WEH1 cells after treated with TNF-a resulted in a higher percentage of cells in 
S phase while the G0/G1 and G2M-phase cells decreased (Shih and Stutman, 1996). 
Although TNF-a does not accelerate or retard cell cycle progression, it can stimulate the 
cells to go to the S phase. TNF-a is believed to kill cells via apoptosis as the cells exit from 
S phase. 
1.1.2.8 Immunomodulatory Effects: 
The immunomodulatory effects of TNF-a involves a wide range of effector cells. 
Regarding to the tumor cells, TNF-a can up-regulate the HLA gene expression and enhance 
the induction of class I and II HLA antigens by EFN-a on tumor cells hence making the 
6 
recognition by effector cells easier (Pfizenmaier et. al., 1987). TNF-a also mediates 
macrophages cytotoxicity by inducing the macrophage to generate peroxide. TNF-a can 
also stimulate macrophages to produce TNF, which in tum can enhance the cytotoxicity of 
macrophages and stimulate other effector cells (Urban et. al., 1986). TNF-a can also 
stimulate the release ofEL-1 by macrophages and endothelial cells, which in tum activates 
the T cells to become highly cytotoxic (Old, 1987). TNF-a increases TNF receptors on T 
cells, making them more sensitive to TNF-a action (Scheurich et. al., 1987)，and it induces 
EL-2 receptors on T cells, leading to mixed lymphocyte reaction (Shalaby et. a/.，1985). 
The effect of TNF-a on neutrophil is not limited to the enhancement of peroxide generation 
and phagocytosis (Larrick et. cd., 1986; Shalaby et. al., 1985), but also involves the increase 
of neutrophil adherence to endothelial surfaces. This effect is achieved by the induction of 
adherence antigen on both endothelial and neutrophil cell surface. This process is very 
important for hemorrhagic necrosis of tumor cells (KlebanofF et. al., 1986). TNF-a can 
also increase the efflux of neutrophils out of blood vessels, and plays a very important role 
in the chemotaxis of leukocytes and monocytes (Ming et. al., 1987). Cytolytic activity of 
human natural killer cells is also enhanced by TNF-a. TNF treatment can also produce 
tumor-specific immunity, making the re-establishment of tumor from the same cell line 
impossible. 
1.1.3 Resistance ofCells to TNF-a: 
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Sensitive Cell in vitro: Cell Type: 
B6MS2 Chemically induced sarcoma 
B6MS5 Chemically induced sarcoma 
CMS4 Chemically induced sarcoma 
CMS16 Chemically induced sarcoma 
L929 Fibroblast 
MethA Chemically induced sarcoma 
MMT Breast carcinoma 
WEHI-164 Sarcoma 
Sensitive Cell in vivo: Cell Type: 
EAT Ehrlich ascites 
Colon 26 Colonic carcinoma 
MM46 Mammary tumor 
MH134 Hepatoma 
Table 1.1 Murine Cancer CeIIs Sensitive to TNF-a in vitro and in vivo QPennica et. al., 
1987; Asher et. aL, 1987). 
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Sensitive Cell in vitro: Cell Type: 
BT-2Q Breast carcinoma 
BT-475 Breast carcinoma 
MCF-7 Breast carcinoma 
ME180 Cervical carcinoma 
SK-MEL-109 Melanoma . 
SK-OV-4 Ovarian carcinoma 
WTOR Colon carcinoma 
Sensitive Cell in vivo: Cell Type: 
SEKI Melanoma 
MHV-1 Melanoma 
MKN450 Gastric carcinoma 
KATO III Gastric carcinoma 
Table 1.2 Human Cancer Cells Sensitive to TNF-a in vitro and in vivo p*ennica et. 
aL, 1987; Asher et. al., 1987). 
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Murine Resistant Cells: Cell Type: 
B16F10 Chemically induced sarcoma 
CMT-93 Rectal carcinoma 
S49 Lymphoma 
Human Resistant Cells: Cell Type: . 
HT-1080 Fibrosarcoma 
Calu-3 Lung carcinoma 
G361 Melanoma 
Hela Cervical carcinoma 
HT-29 Colon carcinoma 
KB Oral epidermoid carcinoma 
RD Rhabdosarcoma 
SK-UT-1 Uterine carcinoma 
T24 Bladder carcinoma 
Table 1.3 Murine and Human Cancer Cells Resistant to TNF-a in vitro pPennica et al., 1987). . 
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TNF treatment is found to be effective against numerous cells in vitro and in vivo. 
Table 1.1 and 1.2 show the sensitive murine and human cells, respectively. Despite the 
strong cytotoxic effect of TNF-a, many tumor cells are resistant to the treatment. Those 
include a number of lung carcinoma, melanoma, cervical carcinoma, colon carcinoma, and 
ovarian carcinoma (Table 1.3) O^ennica et. al., 1987). Resistance or insensitivity of tumor 
cells to TNF-a may be due to the endogenous TNF-a production by the tumor cells itsetf. 
Challenge of cells with increasing concentration of TNF-a induces resistance in cells and 
endogenous TNF-a production (Spriggs et. al., 1987). In addition, protein kinase C 
pPKC) can also increase TNF-a production in tumor cells (y^oo - et. aL, 1996), and the 
addition of staurosporine, an inhibitor of PKC, can enhance the cells' TNF sensitivity ^"ier 
et. al, 1993). The endogenously produced TNF-a occupies TNF receptors, and at the 
same time, down-regulates the production ofTNF receptor (Spriggs et. a/.，1987). The 
endogenous TNF-a is believed to have occupied the newly generated TNF receptors before 
they reach at the cell surface, and thus the receptors-TNF-a complex may be digested 
before reaching at the cell surface. Resistance can also be achieved by having low level of 
R55 receptor expression and absence ofTNF signaling through TNF receptor (Cai et. al., 
1997). TNP receptor R55 is more important in carrying out the cytotoxicity of TNF-a. 
Overexpression of heat shock proteins (hsp) and superoxide dismutase (SOD) can also 
confer resistance in tumor cells (Jaattela et, al., 1992; Li and Oberly, 1997). 
1.1.4 Clinical Studies: 
11 
A phase II clinical study of TNF treatment was conducted in Japan to treat 60 skin 
cancer patients. Of these 60 patients, 11 resulted in complete disappearance of tumor. 
Sixty-three percent of cases resulted in reduction in tumor size of 50% or more in 2 
directions, reduction of 70% or more in 3 directions, or complete disappearance (Taguchi 
et. al, 1992). Another study in USA was done with 32 patients with refractory ascites. 
Seventeen out of the 32 patients had complete resolution of ascites, and 14 had over 50% 
decrease in ascites volume fReichman et. al., 1989). In treating Kaposi's sarcoma, 3 out of 
16 resulted in complete disappearance of tumor and another 12 resulted in decrease in 
cross-sectional area ^Cahn et. al., 1989). All of these clinical studies showed that TNF 
treatment was very effective. However, the treatment is limited by the resistance of some 
cancer types, including advanced colorectal carcinoma, metastatic colorectal 
adenocarcinoma, pancreatic and gastric cancers, metastatic renal cell carcinoma, and renal 
cell carcinoma (Spriggs and Yates, 1992). 
1.1.5 Side Effects: 
Another limitation to the use of TNF treatment is its severe side effects. In the 
Japan's clinical study, 51 patients out of 60 showed side effects. The most common side 
effect was fever. About 57% of cases was reported. Other side effects were chills, general 
malaise，anorexia, hypotension, headache, nausea;'vomiting, local pain at injection site, 
redness，swelling, and many other symptoms (Taguchi et, cd, 1992). Even more severe is 
12 
the sepsis syndrome, which includes fever, increase of cardiac output, decrease in systemic 
vascular resistance and the need for fluid resuscitation and inotropes. The toxicity can be so 
severe that the patients may have to stay in ICU (Zwaveling et. al, 1996). Sometimes the 
treatment can be so toxic that it had to be aborted. These side effects, especially 
hypotension, very often limit the dosage that can be used in TNF treatment. 
13 
1.2 Hyperthermia and Cancer Treatment: 
Hyperthermia is known to have the ability to sensitize cells, even the resistant ones, 
to ionizing radiation and several chemotherapeutic agents, and thus potentiates the 
cytotoxic effect of many treatments. Due to this reason, hyperthermia is used in 
combination with many cancer treatments, especially in handling resistant cancer cells. 
Hyperthermia means that "the local tumor, the tumor region or even the whole body ofthe 
patient has to be heated to temperatures between 40°C to 45°C for a certain time" (Streffer， 
1987). However, in the case of in vivo study, 42°C is the maximum temperature that can be 
used. Temperatures higher than 42°C of whole body hyperthermia are not tolerated by rats, 
rabbit, dogs and human (Pettigrew et. al., 1974; Bull, 1983). Exposure of mice to 41"C or 
42°C over one hour are almost invariably fatal (Hahn, 1982). Local hyperthermia can be 
conducted at temperatures over 42°C. Fixed-temperature hyperthermia is conducted by 
heating the tumor cells to a fixed temperature throughout the whole hyperthermia 
treatment. A new heating method is later proposed: step-down hyperthermia. It is claimed 
that "a relatively short exposure to a high temperature (>43°C) sensitizing treatment 
increases the heat killing effect of a lower temperature (<42°C) test treatment, resulting in 
thermosensitization" ^Gostergaard et. al., 1996). Step-up hyperthermia is believed to be 
ineffective due to the development of thermotolerence. 
14 
1.2.1 Hyperthermic Agents: 
Hyperthermia can be induced using a number of agents. Localized and regional 
hyperthermia can be done using radiofrequency applicators, including electrical and 
magnetical, and microwave applicators. Interstitial techniques include the use of 
radiofrequency electrodes, microwave antennas, ultrasound applicators, and heating of 
implanted ferromagnetic material OH[and, 1987). Heating by immersing part of the body or 
the whole body of the subject into a waterbath is frequently done during in vivo study, and 
an Aquatherm system is used to treat human patients in clinical study OECatschinski et. al., 
1997; Robins et, al., 1994). Hyperthermia perfusion is also performed in clinical settings by 
circulating heated perfusate to the tumor region (Creech and Krementz, 1968; Zwaveling 
et. al., 1996). 
1.2.2 Intrinsic Heat Sensitivity: 
Heat is favorably used in cancer treatments because tumor cells are often more 
sensitive than normal cells to heat. This is because tumor cells, especially those which are 
distant from blood vessels, are hypoxic. In addition, tumor cells have high glycolysis level. 
These lead to anaerobic glycolysis and thus the production of lactic acid. The decrease in 
15 
pH，as a result, sensitizes the tumor cells to heat. The intrinsic heat sensitivity of cells is 
determined by a number of factors. First, it is cell-cycle dependent. Cells at S phase are 
more sensitive, probably due to aberrant DNA replication. Gl-phase cells are least sensitive 
(Bhuyan, 1979; Dewey et. aI., 1978; Read et. al., 1983; Sapareto et. aL, 1978; Westra and 
Dewey, 1971). 
Secondly, heat sensitivity is influenced by metabolic situation. Deprivation of 
oxygen, as explained before, would make the cells more sensitive to heat. Hypoxic cells 
produce lactic acid and make the pH acidic, thus making themselves more sensitive to heat 
(Vexler and Litinskaya, 1986). Deficiency in nutrients, such as amino acids and glucose, 
would also sensitize the cells to heat (Calderwood et. aL, 1985; Gome et, al, 1985; Lanks 
扎 al., 1986; Vidair and Dewwy, 1987). 
Calcium imbalance is also a factor contributing to increased intrinsic heat sensitivity. 
Uncontrolled Ca?+ influx during heat shock would lead to cell death. Inhibition of 
calmoldulin or increase of extracellular Ca^^ can potentiate hyperthermic cell killing 
OVTalhotra et. aL, 1986; Wiegant et. al., 1987). Acidic intracellular pH can also increase the 
cell's heat sensitivity ^Li and Liu, 1997). Production ofhsp，however, is not related to 
intrinsic heat sensitivity of cells but contributes to the development of thermotolerance 
O^over, 1992). 
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1.2.3 Mechanisms of Action: 
1.2.3.1 Depolarization ofMembrane Potential: 
Hyperthermia can increase the intracellular cation (K+) concentration. Intracellular 
K+ is mainly regulated by active influx ofK+ through the Na7K+ pump, and passive influx or 
efflux of K+ through K+ leak channels in the cell membrane, which is dependent on the 
concentration gradient. Hyperthermia depolarizes the membrane potential oftumor cells by 
accelerating the function of Na+/K+ pump, and impairs the K+ leakage channels. The 
depolarized condition leads to cell death O^ishida et. al., 1997). 
1.2.3.2 Reduction of glucose transport and DNA. mRNA and Protein Svnthesis: 
Glucose is a major energy source of tumor cells. Decrease in glucose transport can 
slow down the growth of tumor cell, or even worse, can results in tumor regression. 
Hyperthermia can reduce the rate of glucose transport ^"ung and Lam, 1988). The 
reduction is due to decrease in the number of glucose carrier, rather than alternation of 
carrier structure. DNA, mRNA and protein synthesis are also reduced by hyperthermia. 
i-2.3.3 Decrease ofIntracellular pH: 
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Hyperthermia at 43°C can cause significant decrease in intracellular pH. 
Acidification is reversible when temperature retums to normal, but this increase of 
intracellular pH is dependent on the N a W antiporter. Ifthe function ofNa+/HT antiporter 
is distorted, acidification is not reversible. Acidification of cell leads to growth suppression 
(Lui et. aL, 1995). 
1.2.3.4 Calcium Imbalance-
According to Wieder and Fox (1995), hyperthermia induces the influx of calcium. 
The increase in intracellular Ca^ + is rapid, reaching a plateau after 5 minutes. However, this 
increase is not related to cell death. 
1.2.3.5 Effect on Nucleolar Protein: 
Protein B23 is a nucleolar phosphoprotein which is more abundant in tumor and 
growing cells than in normal resting cells. It may function in the assembly of ribosomal 
proteins into rRNA. Hyperthermia was found to decrease the amount ofintact B23 protein 
and that was correlated with survival (Lui et. al., 1993). Hyperthermia may change the 
conformation of B23 protein, and mRNA and protein synthesis may be slowed down 
because of this. 
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1.2.3.6 Apoptosis: 
Hyperthermia can induce both necrosis and apoptosis. Severe hyperthermic 
treatment usually results in necrosis, whereas mild hyperthermia enhances apoptosis 
OFairbaim et. al., 1995; Sakaguchi et. al., 1995; Yonezawa et. al, 1996). 
1.2.3.7 Induction of Autologous Tumor Killing: 
Brief exposure of tumor cells to hyperthermia increases their susceptibility to lysis 
by autologous blood lymphocytes. This is due to the induction of production of hsp70. 
The hsp70 is recognized by y5T cells and thus the stressed cells bearing hsp70 are lysed 
OVei et. al., 1996). 
1.2.3.8 Blood Flow. Tumor Oxygenation and Vascular Damage: 
In vivo study confirmed that hyperthermia can increase blood flow and tumor 
oxygenation. This occurs when mild hyperthermia is applied (Song et. al., 1996). Hypoxic 
cells can be re-oxygenated after mild hyperthermia; however, when high-temperature 
heating is applied, vascular damage would be resulted. Cells may die due to deprivation of 
energy, or metastasis may be induced O^rano and Kahn, 1983). 
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1.2.4 Clinical Studies: 
Clinical study using deep microwave hyperthermia in treatment for metastatic tumor 
of the liver was done. Hyperthermia treatment resulted in 33% of patients who experienced 
less than 50% regression. Effectiveness increased when it was combined with radiotherapy 
and chemotherapy. The study concluded that although effective therapy for patients with 
metastatic liver disease and large tumor volume was hard to achieve, hyperthermia in 
combination with radiotherapy and/or chemotherapy may be a useful treatment in this 
difficult clinical situation (Petrovich et. al., 1988). 
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1.3 Combined Treatment: 
Many cancer treatments are now done in combination to improve effectiveness and 
reduce side effects at the same time. TNF-a have been used in combination with 
immunotherapeutic drugs, such as interferon and interleukin, and chemotherapeutic drug, 
such as doxorubicin and etoposide (Ruggiero and Baglioni, 1987; Demetri et. aL，1989; 
McIntosh et. al., 1989; Yang et. aL, 1990; Orr et. al., 1989). Hyperthermia is also used 
frequently to enhance the cytotoxic effect of many chemotherapy, for example, carboplatin, 
and radiotherapy OVfizuuchi et, aL, 1996; Katschinski et. aL, 1997; Zywietz et. al., 1997). 
TNF-a will not be an exception. As mentioned before, the use of TNF-a in cancer 
treatment is often limited by its toxicity. Hyperthermia can enhance the anti-tumor effect of 
TNF-a, so that the dosage of TNF-a, and hence the side effect, can be reduced. TNF-a 
plus heat is actually a natural combined treatment, since TNF-a itself induces inflammation 
in patients. Investigation on the use of hyperthermia in cancer treatment was originated 
from the observation ofBusch in 1868 on tumor regression after streptococcus erysipelatis 
infection, which lead to fever. The agent that caused tumor regression was later discovered 
to be TNF-a. The combination with hyperthermia is believed to be able to conquer the 
TNF-a resistant tumor cells. 
21 
1.3.1 Combined Treatment with TNF-a and Fixed-temperature Hyperthermia: 
One type of hyperthermia used in combination with TNF-a is fixed-temperature 
hyperthermia. TNF + fixed-temperature hyperthermia treatment has been tested on a 
number of tumor cells. Extensive cell killing was found for L929, as well as in TNF-a 
resistant cell line, EMT-6, if TNF-a was applied 1 hour before heating at 43°C for 1 hour 
and 1.5 hour, respectively (Tomasovic et. al, 1992). Another study produced a similar 
result. Viability ofL929 and EMT-6 were significantly reduced after the cells were treated 
with TNF-a 1 hour before heat treatment at 43°C for 1 or 1.5 hour, or at 40.5�C of 24 
hours. DNA fragmentation was found to increase with decreasing viability (Tomasovic et. 
al., 1994). Hyperthermia had also enhanced the effect of TNF-a on human colon tumor 
DLD-1 and HCT-15 (Klostergaard et. al., 1992). 
1.3.2 Combined Treatment with TNF + Step-down Hyperthermia: 
A recent study was done on murine and human tumor cells to investigate the 
effectiveness of combined treatment of TNF + step-down hyperthermia. Sensitivities of 
both the sensitive L929 and resistant EMT-6 were enhanced by TNF-a and heating at 43°C 
for 30 minutes fL929 cells) or 60 minutes ^MT-6 cells) and then at 40�C for 24 hours. 
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Human sensitive HCT-15 colon adenocarcinoma, and resistant DLD-1 colon 
adenocarcinoma were also found to be very sensitive to TNF + step-down hyperthermia 
treatment but three normal cells were unaffected (Klostergaard et. al,, 1996). 
1.3.3 In Vivo Study: 
Investigation on the effectiveness ofTNF + hyperthermia against tumor cells in vivo 
has recently begun. Its effectiveness against Meth A sarcoma was tested by injecting the 
mice with 1000U ofTNF-a per mouse and heated at 40°C for 30 minutes. The anti-tumor 
effect was evaluated based on the extent of necrosis over the tumor surface. Five out of 5 
mice treated with TNF + fixed-temperature hyperthermia were classified as complete cure 
(Watanabe et. al., 1988). 
Another study against Meth A was done using the same treatment protocol. 
Synergistic effect was found in the inhibition of metastatic tumor growth . The result was 
determined by counting the pulmonary surface nodules O^iitsu et. al., 1988). 
Even on highly resistant cell, radiation-induced fibrosarcoma QRIF-l) was also 
sensitive to TNF + heating at 42.5�C for 30 minutes. Doubling time ofcells have markedly 
mcrease and the X-ray dose needed to sterilize the cells was reduced after the combined 
treatment. 
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1.3.4 Sequence of Treatment: 
Sequence of treatment is very important in maximizing the treatments' effectiveness. 
It is believed that heating before TNF-a would lead to ineffectiveness due to the production 
ofhsp. Tomasovic et. al (1992) found out that treating the cells 1-4 hours before heat 
gave a better cytotoxicity and TNF treatment 1-4 hours after heat reduced or eliminated the 
enhanced cell killing. In a study in 1992, they found out that treating the cells 2 or 4 hours 
before heat resulted in higher cytotoxicity (Tomasovic et. al., 1992). 
1.3.5 Proposed Mechanism of Synergism: 
There may be a number of ways in which TNF-a and hyperthermia cooperate to 
enhance anti-tumor effect of the treatment. Heat was found to accelerate the turnover rate 
ofTNF complex 0^iitsu et. aL, 1988). The increased turnover rate might have a role in 
speeding up the signal transduction. Srinivason et. al. (1990) also found increased damage 
to capillary endothelial cells and accumulation of neutrophils in the capillaries of tumors, 
suggesting an interaction between the two individual anti-tumor treatments in damaging the 
vasculature, compromising the microcirculation, and thus leading to ischemic tumor 
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necrosis. Klostergaard et. al. (1996) speculated that the enhancement of effect ofTNF + 
step-down hyperthermia treatment was due to the inhibition of recovery of cells. Protein 
synthesis was inhibited by heat, and proteins in the nucleus might also aggregate. Recovery 
of such damages might be inhibited by step-down hyperthermia, and hence synthesis of TNF 
protective proteins, or proteins involved in TNF damage repair might be blocked, and cell 
death would therefore be resulted as proposed by them. 
25 
1.4 Objective of Study: 
1.4.1 Sequence of Treatments: 
Although combined treatment of TNF and hyperthermia was under investigation for 
quite some times, not much attempt has been made to find out the exact optimal sequence 
of treatment. Treatment order is known to be very important and can result in either 
enhancement of effect or total elimination of effect. The optimal time for TNF 
administration might be related to the existence of synergism between the two treatments. 
When administered at the appropriate time, TNF-a might be able to cooperate with heat 
synergistically to give the best result, so the best TNF administration time is very important. 
Simply finding out the order of treatment is not enough, the interval between TNF and 
hyperthermia treatment is also very critical and the optimal TNF administration time must 
be found out. Tomasovic et. al. (1989) had discovered that TNF-a was best administered 
1-4 hours before heat, but the exact optimal TNF administration time for TNF + fixed-
temperature hyperthermia has not been determined. The sequence of TNF + step-down 
hyperthermia treatment is still unknown. The optimal sequence of these treatments will be 
investigated in this study. 
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1.4.2 Comparison of Treatments' Effectiveness: 
Many studies have confirmed the effectiveness of TNF + fixed-temperature 
hyperthermia and TNF + step-down hyperthermia treatments, but their effectiveness are 
seldom compared. Klostergaard et. aI. (1996) found out that TNF + step-down 
hyperthermia produced better anti-proliferative effect on L929, EMT-6, HT-15, and DLD-1 
cells than that in treatment of TNF + heating at 43�C for 1 hour. However, since the 
heating duration were different, ones cannot make a conclusion that TNF + step-down 
hyperthermia is better than TNF + fixed-temperature hyperthermia. In this study, the 
effectiveness ofTNF + fixed-temperature hyperthermia and TNF + step-down hyperthermia 
treatments with the same heating duration on Ehrlich ascites tumor cells and human 
leukemia HL-60 cells will be compared. Step-down hyperthermia with heating at 43�C for 
1 hour and 2h at 40°C, 43X for 2 hours and 40°C for 1 hour, and 43°C for 1 hour and 40°C 
for 24 hours will examined. The latter resembles the treatment done by Klostergaard et. al. 
(1996). The cell death pathway resulted from these treatments will be examined. 
1.4.3 Effect on Normal Cell: 
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Effectiveness in killing tumor cells should not be the sole criteria in evaluating the 
combined treatments. Highly toxic treatment which also kill normal cell would not be 
desirable. This study will find out the treatments' effect on human coronar/ artery 
endothelial cells (HCAEC) which is very sensitive to stress. 
1.4.4 Effect on Distribution ofCells in Cell Cycle Phases: 
Effort on discovery of mechanism of synergism is mostly focused on the potentiation 
ofTNF-a effect by hyperthermia. Little attention has been paid to the possibility that TNF-
cc can also sensitize the cells to heat. Since TNF-a can increase the S-phase cells, and S-
phase cells are more sensitive to heat, it is very possible that TNF-a can sensitize the cells in 
this way. In addition, different TNF administration time might interfere with this synergism. 
Effect ofdifFerent TNF administration time on this distribution ofcells at different cell cycle 
phases will by examined. 
1.4.5 In Vivo Study: 
28 
Most of the investigation of combined treatment with TNF and hyperthermia were 
done in vitro. Whether these treatments are effective against tumor bore in animal's body is 
rarely tested. In vivo studies on TNF + fixed-temperature hyperthermia had been performed 
but most of them were done on solid tumors. Effectiveness against tumors such as 
leukemia and ascites, which require to be heated using whole-body hyperthermia, is rarely 
evaluated. In addition, the effectiveness of the treatment in recent in vivo studies was 
evaluated empirically. Evaluations were usually done by counting the occurrence of 
metastasis or observing the extent of necrosis of surface area. In this study, trypan blue 
exclusion assay will be performed to calculate the exact percentage of viable cells after 
treatment. Such exact figures would show clearly the growth suppression effect, and allow 
the calculation of additive effect so that the existence of synergism can be speculated. In 
addition, TNF + step-down hyperthermia has never been tried on animal model. TNF + 
fixed-temperature hyperthermia and TNF + step-down hyperthermia against tumor bore in 
animals will be compared in this study. The reversed-sequence treatment, heating before 
TNF treatment, will also be examined. 
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Chapter Two: Materials and Methods 
2.1 Materials: 
2.1.1 For Cell Culture: 
RPMI Medium 1640 with L-glutamin and 25mM HEPES buffer; fetal bovine serum; 
and penicillin/streptomycin (10,000 U/ml penicillin G sodium plus 10,000 pig/ml 
streptomycin sulfate in 0.85% saline) were all purchased from GibcoBRL, New York, USA. 
Sodium Hydrogen Carbonate O^aHCO3) was supplied by Riedel-De Haen, 
Germany. 
EGM-MV Bullet kit was purchased from Clonetics Laboratories, Walkersvilles, 
USA. It included Endothelial Cell Basal Medium (EBM), at a 0.15mM calcium 
concentration, and SingleQuots that contained the following supplements (concentrations of 
supplements in each SingleQuot are indicated): 
lOng/ml human recombinant Epidermal Growth Factor, 0.5ml 
l.Ong/ml Hydrocortisone, 0.5ml 
50mg/ml Gentamicin, 50^ig/ml Amphotericin-B, 0.5ml 
3mg/ml Bovine Brain Extract, 2ml; and 25ml FBS. 
ReagentPack, which included HEPES Buffered Saline Solution OHBSS)， 
Trypsiny^DTA solution, and Trypsin Neutralizing solution, was purchased from Clonetics 
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Laboratories. 
Dimethyl Sulfoxide pMSO) was supplied by Sigma Chemical Co., St. Louis, Mo.， 
USA. 
2.1.2 In vitro Treatments: 
Human recombinant tumor necrosis factor alpha (rhTNF-a) was purchased from R 
& D Systems, Minneapolis, MN, USA. Its activity was measured to have an ED50 of0.02-
0.05ngArJ after incubation with L929 cells for 24 hours. 
Bovine Serum Albumin, Trypan Blue solution and Neutral Red were purchased from 
Sigma Chemical Co.. 
2.1.3 DNA Electrophoresis: 
Sodium chloride QSFaCl), potassium choloride ^CC1), and potassium phosphate 
(KH2PO4) for phosphate buffered saline were purchased from Sigma Chemical Co.; and 
sodium hydrogen phosphate OS[a2HPO4) was purchased from Riedel-De Haen Chemicals. 
Ingredients of lysis buffer or TE buffer, such as Tris and SDS were from United 
State Biochemical (USB), Amersham, Ohio, USA and EDTA was from Riedel-De Haen 
Chemicals. 
Phenol, equilibrated with Tris buffer (pH>8.0), and TBE Buffer Concentrate (lOX) 
containing 10X 0.089M Tris, 10X 0.89 Boric acid and 2mM tetrasodium EDTA pH8.0 
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were purchased from USB. 
Proteinase K (14 U/mg), Ribonuclease A (102 Kunitz units/mg), agarose, and 
ethidium bromide (5mg/ml) were supplied by Sigma Chemicals Co.. 
Chloroform (CHCl3) and ethanol (99.7-100%) were obtained from BDH Laboratory 
Supplies, Poole, England. 
Methyl butanol (isoamyl alcohol) (98%) was purchased from Riedel-De Haen 
Chemicals. 
100 Base-Pair DNA Marker (lp,g/pil in TE buffer) was obtained from Pharmacia 
Biotech Co., Uppsala, Sweden. 
Geneclean Grade Gel loading dye (bromophenol blue and glycerol) was supplied by 
Bio 101, Inc., California, USA. 
2.1.4 Flow Cytometry: 
Propidium Iodide and sheath fluid were supplied by Sigma Chemical Co. and Becton 
Dickson Canada, Inc., Ontario, Canada, respectively. 
2.1.5 In Vivo Study: 
Pentobarbital was supplied by Sigma Chemical Co.. 
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2.2 Reagent Preparation: 
2.2.1 Culture Media: 
Each pack ofRPMI medium 1640 was dissolved in 950ml of distilled water and 2g 
ofNaHCO3 was added to the solution. Acidity was adjusted to about pH7.2 with lM HC1 
or NaOH and then distilled water was added to make up to 1 liter. The medium was sterile 
filtered in culture hood with sterile 2|^m filter. 50ml of Fetal Bovine Serum and 5ml of 
penicillin/streptomycin were added to 450ml ofRPMI before use. 
EGM-MV was prepared by mixing the EGM with a cryovial of SingleQuot. 
2.2.2 Human Recombinant Tumor Necrosis Factor alpha (rhTNF-a): 
Reconstitution of rhTNF-a was done by dissolving the rhTNF-a in 2mg/ml of 
bovine serum albumin in phosphate buffered saline OPBS). lOng/^il aliquots of the rhTNF-a 
solution were stored at -70�C and was diluted to desired concentrations with respective 
culture medium before adding to the cells cultures. 
2.2.3 Phosphate Buffered Saline (PBS): 
80g ofNaCl, 2g ofKCl, 2g ofKH2PO4and 14.4g ofNa2HPO4-2H2O was dissolved 
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in lL of distilled water to make up a 10-times concentrated PBS. It was stored at 4°C and 
diluted 10-fold before use. 
2.2.4 Lysis Buffer: 
lOmM Tris-HCl plus 200mM EDTA solution was stored at 4°C and diluted with 
equal volume of 2% SDS to make up a 5mM Tris-HCl, 100mM EDTA and 1% SDS 
solution. It was adjusted to pH8.0 and stored at room temperature. 
2.2.5 TE Buffer: 
TE buffer was made up of lOmM Tris-HCl and 0.5mM EDTA (pH7.4) and stored 
at room temperature. 
2.2.6 Proteinase K and Ribonuclease A (RNase A): 
20mg ofproteinase K was dissolved in 1ml of distilled water, and lOmg ofRNase A 
was dissolved in 1ml ofTE buffer. Aliquots of these were stored at -20°C. 
2.2.7 100-Base-Pair DNA Marker: 
6\x\ of l^tg/^l DNA marker was diluted with 96^il of TE buffer and 20^il of loading 
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dye to make up a solution of 0.5^ig DNA/10|il TE with dye. Aliquots of 10|il were stored 
at -20X. 
2.2.8 Propidium Iodide (PQ: 
Propidium iodide solution was prepared by dissolving 2mg ofPI in 1ml of PBS and 
stored at 4°C. 
2.3 Methods: 
2.3.1 Cell Culture: 
2.3.1.1 Ehrlich Ascitic Tumor fEAT) and Human Leukemia (HL-60): 
EAT and HL-60 were purchased from American Type Culture Collection, 
Rockville, Maryland, USA. The cells were thawed and grown in RPMI with 10% FBS and 
5% penicillin/streptomycin. EAT and HL-60 were passed to 3 and 5 passages, respectively, 
and one of the subcultures was frozen in freezing mixture containing 50% fetal bovine 
serum, 10% DMSO and 40% RPMI, and stored in -70°C liquid nitrogen. The cells grown 
in medium were not used in experiments until after 3 to 5 passages. EAT was passed to 
new medium every 2-3 days. It was passed to a maximum of 40 passages before thawing a 
new sub-cultured cells from the storage. HL-60 was passed twice a week, and was passed 
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to a maximum of 20 passages before thawing the sub-cultured cells. 
2.3.1.2 Human Coronarv Arterv Endothelial Cells mCAECV 
HCAEC was purchased from Clonetics Co., Walkersville, USA. The cells were 
grown in Endothelial Cells Growth medium with supplements (EGM-MV) according to the 
instruction as described by the Clonetics EndoPack. The cells were passed once a week 
when the cells were at 70-90% confluence. The cells were washed with HBSS (5ml per 
25cm^ area) and then trypsinized with trypsin;TEDTA solution. After 5-6 minutes, the cells 
were observed under microscope. The cells should have detached from the bottom of the 
flask and showed shinny round cell surface. The flask was shaken briefly to ensure 
detachment of most of the cells from the flask surface. Five ml of trypsin neutralizing 
solution was added into the flask to neutralize the trypsin/EDTA solution. The cell 
suspension was transferred to 15ml falcon tube and centrifuged at l,500rpm for 3 minutes 
using EEC Centra MP4R Centrifuge. Supernatant was removed and the cells were 
resuspended with EGM-MV. The cells used for experiments are those grown within 15 
population doublings. 
2.3.2 In vitro Experiments: 
Two milliliters of 5xlO^ cells/ml of HL-60 cells or 2ml of 1.5xlO^ cells/ml of EAT 
cells were seeded on 6-well plates or 35mm tissue culture dishes for 20 hours at 37°C with 
5% CO2 in air before treatments. The normal cells HCAEC were seeded at a concentration 
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of lxlO^ cells/ml on 96-well plates. Two hundred i^l ofcell suspension was added to each 
well and incubated for 20 hours at 3TC before treatment. For all three cell lines, the cells 
were transferred back to 37�C after treatments and incubated for 24 hours before harvesting 
in the experiments of sequence determination for TNF + Fixed-temperature hyperthermia 
and TNF + Step-down hyperthermia 2 treatments (refer to section 2.3.4), or until the end 
of31-hour total treatment time in the comparison of treatment efficacy. In the experiment 
of TNF + Step-down hyperthermia 3 sequence determination, the cells were incubated at 
40°C, which was the last step of Step-down hyperthermia 3 treatment, for 24 hours before 
cell harvesting. 
2.3.3 Tumor Necrosis Factor Treatment: 
Dosage for both HL-60 and HCAEC was lOOng/ml (final concentration) and dosage 
for EAT was 0.05ng/ml (final concentration). The cells were incubated wit rhTNF-a at 
37�C at times other than hyperthermia treatments and were incubated with it throughout the 
whole experiments. 
2.3.4 Hyperthermia Treatments: 
Coming 6-well plates or 35mm tissue culture dishes were used in all treatments 
involved hyperthermia for both HL-60 and EAT cells to ensure constant surface area and 
thus constant heat dosage to the cells. Ninety-six-well plates were used for HCAEC cells 
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since it had to be used to determine the absorbance using ELISA plate reader. 
Hyperthermia was performed by procedures similar to those as described by Lui et. al. 
(1993). Cells cultured on plates were put into an air-tight sac filled with 5% CO2 in air and 
put into an incubator pre-heated at 43°C or 40�C with a fluctuation of 0.5°C. For those 
cells treated with step-down hyperthermia, the cells were heated at 43°C for the desired 
period of time and then transferred to another incubator preheated at 40�C. After the 
desired period of time, the cells were transferred back to 37�C. Four different kinds of 
hyperthermia treatments were performed: Fixed-temperature hyperthermia was done by 
heating at 43°C for 3 hours; step-down hyperthermia 1 represented heat treatment at 43°C 
for lhour and then at 40°C for 2 hours; step-down hyperthermia 2 meant heating at 43�C 
for 2 hours and then at 40�C for 1 hour; step-down hyperthermia 3 was a prolonged heat 
treatment with 43T heat for 1 hour and 40°C for 24 hours. 
2.3.5 Cell Counting: 
2.3.5.1 Trypan Blue Exclusion Assay: 
Trypan blue stain was used to estimate the viability and relative cell density of 
suspension cells, HL-60 and EAT. This was done by mixing an equal volume oftrypan blue 
with the cells suspension. Viable, as well as dead cells were counted in a hemocytometer 
under microscopy. The results were presented in two forms: relative growth and viability, 
and they were calculated as follows: 
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Relative Growth = % Control = Viable Treated Cells x 100% 
Viable Control Cells 
Percent Viability = % Viability = Viable Treated Cells x 100% 
Total Treated Cells 
Error was calculated using SEM, which was calculated as follows: 
SEM = Standard Deviation x 100% ^ 
where n is the number of samples. 
2.3.5.2 Neutral Red Assav: 
Relative Growth of the HACEC cells was estimated using this assay. After 
treatments, the culture media were washed away using PBS twice and then lOO i^l ofneutral 
red dye was added to each well. The neutral red dye was allowed to be uptaken by the 
viable cells at 37�C for 45 minutes. Excess dye was removed and washed with PBS twice. 
The cells were then air-dried. A hundred ^1 of 1% SDS was added to each well to lyse the 
cells and released the dye from the cells. OD540 was determined using ELISA plate reader. 
The relative growth was calculated as follows: 
% Control = r O D j ^ 1 t ^ - rODj^" | ^ x 100% 
[OD540]controi - [OD540]biank 
2.3.6 Determination of Additive or Synergistic Effect: 
The existence of synergistic effect was determined by first calculating the expected 
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additive results. With the assumption that the fraction of cells killed by rhTNF-a was 
different from those affected by hyperthermia, additive results were calculated by 
multiplying the two percentages of relative growth or percent viability of the two single 
treatments together, so that if rhTNF-a alone kills %v ofcells and hyperthermia alone kills 
%h of cells, the expected percent viability left would be: 
%Viability = %v x %h 
Expected relative growth was calculated as the same way. This figure would give the 
maximum expected additive relative growth or percent viability possible. 
2.3.7 DNA Electrophoresis: 
Cells atlxlO^ after treatments were harvested and washed with 0.5ml PBS. The 
cells were lysed using 0.5ml lysis buffer and vortexed vigorously to prevent clumping. Ten 
ml of 20mg/ml proteinase K was added to each sample to digest structural protein and 
enzymes, including DNase, of the lysed cells. The suspensions were included at 37°C 
waterbath overnight to allow complete digestion. Phenol-chloroform extraction was then 
performed to purify the DNA. Half ml of phenol was added to each mixture and vortexed 
vigorously. Half ml of chloroform-isoamyl alcohol (24:1) was added and it was again 
vortexed vigorously. The mixtures were then centrifuged using Sanyo MSE Micro Centaur 
table-top centrifuge at 10,000rpm for 2 minutes. The mixture would then be separated into 
2 layers. The top was the aqueous layer containing the DNA, and the bottom layer was the 
phenol-chloroform fraction. The aqueous layer was carefully removed to a new tube. 
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Another 0.5ml of chloroform-isoamyl alcohol (24:1) was added to the aqueous layer in the 
new tube to wash away the residual phenol, protein or lipid. The mixtures were vigorously 
mixed and centrifuged at 10,000rpm for 2 minutes using the table-top centrifuge. The 
aqueous layer was removed carefully without disturbing the bottom layer and 46jil of 5M 
NaCl and 1ml of absolute ethanol were added to the aqueous layer. They were mixed 
gently and the DNA was precipitated at -20�C ovemight. The DNA precipitate was 
centrifuged down to the bottom of the tubes using 10,000rpm for 5 minutes with Heraeus 
Sepatech Biofuge B horizontal centrifuge at room temperature, and then at 14,000rpm with 
Eppendorf Centrifuge 5402 for 20 minutes at 4°C. Ethanol was drained away and the DNA 
was dried. The DNA pellet was dissolved in 18 i^l TE buffer and 2 i^l of lOmg/ml ofRNase 
A was added to digest the RNA at 37°C for 1.5 hours. To determine the DNA amount in 
this DNA solution, 2[i\ of the DNA solution was pipetted to 0.5ml of distilled water, 
absorbance at 260nm wavelength was determined using spectrophotometer to estimate the 
DNA amount. All the DNA samples were adjusted to the same concentration with TE 
buffer so that they would all give an OD260 of0.05. Ten i^l ofthe diluted DNA solutions 
were mixed with 2 i^l ofloading buffer. The mixtures were loaded onto 1.5% agarose gel, 
which was prepared by dissolving 0.45g of agarose in 30ml ofTBE buffer. Ten i^l of0.5pig 
100 base-pair DNA marker was also loaded onto the gel. Two hundred and twenty ml of 
TBE buffer was prepared and used as running buffer. Electrophoresis was performed for 2 
hours using 60 volts. The gel after electrophoresis was stained with ethidium bromide 
(0.5^gy'ml) for 30 min and de-stained with distilled water. Picture of the gel profile was 
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taken under UV light. 
2.3.8 Flow Cytometry: 
2.3.8.1 Preparation of Samples: 
Cells at lxlO^ after treatments were harvested and washed once with 0.5ml PBS to 
remove the culture medium. The cells were fixed with 1.5ml 70% ice-cold ethanol 
overnight. The cells would then be permeable to fragmented DNA, and thus necrotic or 
apoptotic cells with fragmented DNA would contain less DNA content due to leakage. 
Fixed cells were centrifuged at 2,500rpm for 5 minutes using the Sanyo MSE Micro 
Centaur table-top centrifuge, and the ethanol was drained away. The pellets were washed 
once with 0.5ml PBS to remove the ethanol and the fixed cells were resuspended with 
0.95ml PBS. Ten pil of lOmg/ml RNase A was added to each sample to digest the RNA 
present in the fixed cells. Forty p,l of 2mg/ml propidium iodide was added to stain the DNA 
of the cells. The samples were vortexed and incubated in 37°C waterbath for 30 minutes in 
dark. Cells with higher DNA content would be stained with more propidium iodide, and 
thus emitted higher intensity of light. The cells would be stained to orange in color. The 
intensity of light of each individual cell, and hence the DNA content of the cells, of each 
sample was analyzed using flow cytometry. 
42 
2.3.8.2 Flow Cytometry Acquisition: 
Pre-experiment washing of the flow cytometer machine was done every time before 
each acquisition. Sheath fluid was replaced by Nanopure water as the transportation 
medium and was allowed to by-pass the filter before entering the machine. Ten % bleach 
was allowed to be run through the passage, through which the sample was transported to 
the optical system and detectors, to clear any blockage. The machine was washed with 
10% bleach for 5 minutes. Nanopure water was then replaced by sheath fluid, which acted 
as the transporting fluid during acquisition, and the machine was then washed with double 
distilled water for another 5 minutes to remove the bleach. The argon ion lasers of the 
optical system would illuminate the cells so that the PI inside the cells would emit light at 
585nm. FL2 detector was used to detect the amount ofPI inside each individual cells. FL2-
area data was collected so that the total amount of light detected from each single cell was 
calculated. About 10,000 cells from each sample were measured. All the samples were 
measured within 60 minutes after incubation. Finally, the machine was washed with double 
distilled water and 10% bleach after use. 
2.3.8.3 Analysis: 
Histograms of FL2-area was plotted and analyzed by setting markers at the Go/Gl 
peak and G2M peak. Fraction of cells at Go/Gi, S, G2M phases were thus calculated. The 
percentage of cells having less DNA, which indicated DNA fragmentation, was also 
calculated and plotted. 
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2.3.9 In vivo Experiments: 
2.3.9.1 Animal Strain: 
Female BALB/c mice, aged 8 weeks, were obtained from the Animal House of the 
Chinese University ofHong Kong. 
2.3.9.2 Cell Line: 
Ehrlich Ascites tumor cells were cultured in culture flask. On day 0，the cells were 
washed with sterile PBS to remove the culture medium. The cells were resuspended with 
sterile PBS and diluted to 5xlO^ cells/ml. Cells suspension of 0.2ml was injected into each 
mouse intraperitoneally. 
2.3.9.3 Tumor Necrosis Factor Treatment: 
rhTNF-a was reconstituted as described before, and diluted to 5ng/^l, 2.5ng/^il, and 
1.25ng/^il using warm sterile PBS. Volume of 0.2ml of these diluted and undiluted rhTNF-
a (that is 2^ig, l^ig, 0.5^ig, and 0.2^g) were injected intraperitoneally into the EAT-bearing 
mice to investigate the dose-response effect of the rhTNF-a on EAT cells. In the 
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experiment of comparing the efficacy of various treatments, a dose of 2\ig of rhTNF-a was 
used. The mice were injected with rhTNF-a on Day 2, 4，and 6. 
2.3.9.4 Hyperthermia Treatments: 
The heat treatment protocol was modified from the method used by Liu (1993). 
The protocols were approved by the Animal Research Ethic Committee, the Chinese 
University of Hong Kong. Fifty ml Falcon tubes were drilled with 15 holes, sized 5mm in 
diameter, at the rear end, to be used as mouse traps. Fig. 2-1 showed a picture of the trap. 
The EAT-bearing mice were put into the traps and the caps were screwed tightly to prevent 
water from getting inside the tubes. They were then immersed into a waterbath preheated 
at 38.5°C or 37.5°C. The traps were held using a test-tube rack in an up-side-down position 
so that the mice were sitting in an up-right position. The holes at the rear end of the tubes 
were less than 2cm from the water level so that the could served as ventilation holes. The 
water level was set at a level slightly above the head level of the mice to ensure constant 
heat transmission, even when the mice stood up. The size of the tubes were only slightly 
larger than the mice so that the mice were only allowed to have minimal space to move 
within the tubes. This close contact between the heated water and the mice would allow 
efficient heat transmission and thus effective hyperthermia treatment. The mice were heated 
at 38.5�C for one hour, in the case of fixed-temperature hyperthermia, or at 38.5�C for 30 
minutes and then at 37.5"C for 30 minutes, in the case of step-down hyperthermia. The 
change of temperature was achieved by adding cool water into the waterbath. The 
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Fig.2-1 Design of Mouse Trap used for Hyperthermia Treatment in vivo. 
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water temperature was controlled automatically by the waterbath with a slight fluctuation of 
O.rC. The mice underwent hyperthermia were treated on Day 2, 4，and 6. An extra 
control was done to test the effect of stress, which might be imposed by being confined 
inside the Falcon tube, on the treatments' effectiveness. The mice were confined inside the 
tube as described before and heated in a waterbath set at room temperature. The treatments 
for comparison included control, which was done by injecting 0.2ml of sterile PBS on the 
three days of treatment; heating at 25°C; TNF treatment; fixed-temperature hyperthermia; 
step-down hyperthermia; TNF + fixed-temperature hyperthermia, which was done by 
injecting the mice with 2p_g of rhTNF-a 4 hours before heating the mice at 38.5"C for one 
hour; TNF + step-down hyperthermia, which was done by injecting 2^ig of rhTNF-a 4 
hours before heating the mice with step-down hyperthermia; and the reversed-sequence 
treatment, which meant fixed-temperature hyperthermia prior to TNF treatment. 
2.3.9.5 Test ofBodv Temperature: 
According to Lui (1993), when the mice were immersed into the waterbath at 
38.5"C, the body temperature of the mice have been reported to go up to 40.5"C 土 0.2°C 
after 16-19 minutes. The body temperature of the EAT-bearing BALB/c mice under this 
protocol was tested again. This was achieved by anaesthetizing the mouse with 
pentobarbital. Eighty pil of 2.5% pentobarbital was diluted to 0.2ml with sterile PBS and 
injected into the mouse intraperitoneally. The mouse lost mobility within 5 minutes. A 
thermistor probe (YSI 402) was inserted into the mouse's rectum. The probe went through 
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the holes at the rear end of the tube and was connected to a thermometer. To prevent the 
probe from sliding out of the mouse's body, cotton puffs were put inside the tube to 
immobilize the probe ^"ig. 2-2). The mouse was put into the tube as described before and 
immersed into the waterbath preheated to 38.5�C. The body temperature was recorded at 
different time intervals for one hour. For monitoring body temperature change in step-
down hyperthermia, the temperature of the waterbath was changed to 37.5"C after 30 
minutes and the body temperature was continued to be monitored. 
2.3.9.6Cell Harvesting: 
EAT-bearing mice after treatments were killed on Day 7 and cells inside their 
abdominal cavity were harvested. The abdominal cavity was flushed thoroughly with PBS 
and the cells were collected until the flushing resulted in clear PBS. The volume of 
collected cells ranged from 3ml to 19ml. Total viable cell numbers were calculated for 
comparison. Number of mice used in each treatment ranged from n = 7 to 12. Results were 
presented in two forms and were calculated as follows: 
% Control = Total Treated Viable Cells x 100% 
Total Control Viable Cells 
% Viability = Total Treated Viable cells x 100% 
Total treated cells 
Error was presented as standard deviation, for the result of dose-response effect, and SEM, 
for the result of comparison of effectiveness. 
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Fig. 2.2 Test of Body Temperature during Hyperthermia in vivo. 
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Chapter Three: Result 
3.1 Optimal Sequence ofTreatments 
Before the efficacy of various combined treatments with TNF-a and hyperthermia 
could be compared, the optimal sequence of treatments had to be determined. The effect of 
different treatment sequences on the cytostaticity and cytotoxicity of the combined 
treatment with TNF-a + fixed-temperature hyperthermia, TNF-a + step-down hyperthermia 
2’ and TNF-a + step-down hyperthermia 3 were examined in this section. The ones 
producing highest growth suppression and cytotoxicity would be used in the future sections. 
The sequence oftreatments were tested on both human and murine cell lines. 
3.1.1 Optimal Sequence of Treatments on Murine EhrIich Ascites Tumor (EAT) cells: 
3 • 1.1 • 1 TNF + Fixed-temperature Hyperthermia: 
To determine the optimal sequence of treatment of TNF-a + fixed-temperature 
hyperthermia, an experiment was done by adding rhTNF-a at different time point before (as 
represented by negative numbers) or after (as represented as by positive numbers) the 
initiation of heat. The result is shown in Fig. 3.1. The combined treatment was very 
effective when rhTNF-a was administered three hours or longer before heat. Effect of 
growth suppression was most severe when rhTNF-a was added 4 hours before fixed-
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Fig. 3.1a Effect ofDifferent Times of TNF Administration on the Relative Growth of 
EAT ceIIs treated with rhTNF-a + Fixed-temperature Hyperthermia. EAT cells at 
1.5xlO^ cells/ml, after seeded for 20 hours at 3TC, were treated with rhTNF-a and/or 
heated at 43�C for 3 hours. Some cells were treated with rhTNF-a 6，4，3, 2, and 1 hour(s) 
before heat (designated by negative numbers) and some were treated with rhTNF-a 0，3， 
and 6 hour(s) after heat (designated by positive numbers). The cells were heated with the 
presence of TNF-a. The cells were incubated at 37°C for 24 hours after heat treatment. 
Viable cells were counted by trypan blue exclusion method. The results are expressed as 
relative growth (%Control). 
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Fig. 3.1b Effect of Different Times of TNF Administration on the Viability of EAT 
cells treated with rhTNF-a + Fixed-temperature Hyperthermia. The protocol was 
similar to that described in Figure 3.1a，except the results are expressed as percent viability 
(%Viability). 
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temperature hyperthermia. Only about 4% of relative growth was observed for this 
treatment as compared to the untreated cells (Fig. 3.1a). Relative growth rose as rhTNF-a 
administration was delayed. The growth suppression effect obviously diminished. 
Nevertheless, combined treatment exerted a stronger effect than either single treatment, 
suggesting that to EAT cells, the reversed-sequence treatment, that is hyperthermia before 
TNF, was also effective in suppressing the proliferation of EAT cells, although the effect 
was weaker. 
Cytotoxic effect of this treatment was highest when rhTNF-a was administered 4 
hours before heat treatment OFig. 3.1b). Less than 10% of viable cells was left. Viability of 
EAT cells rose as TNF-a administration time was delayed. The difference between control 
and the treatments with rhTNF-a added after the initiation o f 4 3 � C were less than 10%. 
The percent of viability of the treatments with these sequences were higher than the result 
calculated by adding the effect of the two single treatments together (that is, 78.86% x 
96.96% = 76.46%). The result suggests that for EAT cells, fixed-temperature heat in the 
reversed-sequence treatment, might have protected the cells from the cytotoxic effect of 
rhTNP-a. 
3• 1.1.2 TNF + Step-down Hyperthermia 2: 
The effect of different TNF administration time on the efficacy of the treatment with 
rhTNF-a and step-down hyperthermia 2 was examined in this section. As indicated in Fig. 
3.2a, the relative growth increased as the TNF administration time was delayed. Treatments 
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with rhTNF-a added 6 hours before step-down hyperthermia 2 produced a significantly 
higher growth suppression than those with other treatments of various TNF administration 
times (p<0.05). Growth of EAT cells was suppressed to as low as 56% of the untreated 
cells. Treatment with t = -4 hour ofTNF administration time could also suppress growth to 
about 60%. Only with these TNF administration times the rhTNF-a + step-down 
hyperthermia 2 treatments could produce growth suppression effect stronger than that 
assumed to be produced by adding the effects of the two single treatments together (TNF x 
SDH2 = 79.0% X 91.71% = 72.45%). The relative growth resulted from the treatments 
with TNF administration time t=0, 3，and 6 were all higher than that resulted from single 
TNF treatment. The result means that step-down hyperthermia 2 in these treatments was 
not only ineffective in suppressing the growth of EAT, but actually blocking the growth 
suppression effect of rhTNF-a. Heating EAT cells with step-down hyperthermia 2 before 
TNF treatment weakened the growth suppression effect of rhTNF-a on EAT. Although 
adding rhTNF-a 2 or 3 hours before step-down hyperthermia 2 did not weaken the growth 
suppression effect ofTNF, the role of step-down hyperthermia 2 in these treatments seemed 
to be negligible. 
Cytotoxic effect of the combined treatment with TNF + step-down hyperthermia 2 
was very mild. The highest cytotoxic effect achieved by this combined treatment was about 
30% pFig. 3.2b), which was resulted from treating the cells with rhTNF-a 6 hours before 
step-down hyperthermia 2. Again, cytotoxic effect diminished gradually as TNF 
administration was delayed. About 90% ofEAT cells survived after this type of combined 
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Fig. 3.2a Effect ofDifferent Times ofTNF Administration on the Relative Growth of 
EAT cells treated with rhTNF-a + Step-down Hyperthermia 2. EAT cells at 1.5xlO^ 
cells/ml, after seeded for 20 hours at 37T, were treated with rhTNF-a and/or heated at 
43°C for 2 hours and then at 40T for 1 hour. Some cells were treated with rhTNF-a 6, 4， 
3，and 2 hours before heat (designated by negative numbers) and some were treated with 
rhTNF-a 0，3，and 6 hour(s) after heat (designated by positive numbers). The cells were 
heated with the presence of TNF-a. The cells were incubated at 37°C for 24 hours after 
heat treatment. Viable cells were counted by trypan blue exclusion method. The results are 
expressed as relative growth (%Control). 
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Fig. 3.2b Effect of Different Times of TNF Administration on the Viability of EAT 
cells treated with rhTNF-a + Step-down Hyperthermia 2. The protocol was similar to 
that described in Figure 3.2a，except the results are expressed as percent viability 
(%Viability). 
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treatment with rhTNF-a added at t=-3, -2，0，3，and 6 hours. If the cytotoxic effect of the 
two single treatments, TNF and step-down hyperthermia 2, were added together, a value of 
76.60% viability was obtained (78.86% x 97.13%). When this value was compared with 
the viability resulted from the combined treatments, less than 7% in difference was 
observed, suggesting that synergistic effect in cytotoxicity might not exist for this treatment 
in EAT cells. 
3 • 1 • 1.3 TNP + Step-down Hyperthermia 3: 
The result for the determination of TNF-a + step-down hyperthermia 3 treatment 
sequence is shown in Fig. 3.3. The growth suppression effect was most severe when 
rhTNF-a was added to EAT cells 4 hours before heating the cells (¥ig. 3.3a). With this 
sequence of treatment, TNF + step-down hyperthermia 3 suppressed the growth of EAT 
cells to only 2% ofthe untreated cells. Treatments with TNF administration time other than 
this showed higher relative growth. The relative growth of treatments with delayed TNF 
administration time were about 15%. Although the growth suppression effect of these 
combined treatments with heat before rhTNF-a was very severe, these treatments did not 
show any synergistic effect. Ifthe growth suppression effect of the two single treatments, 
TNF only and step-down hyperthermia 3 only, were added together, a value of 17.25% was 
obtained (79.00% x 21.84%). This value was only about 2% higher than the relative 
growth obtained for the combined treatments with TNF administration time t=0, 3，and 6 
hours. The result showed that a late TNF administration time would not only make the 
combined treatment less effective in suppressing EAT cells' growth, it would also cause 
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Fig. 3.3a Effect ofDifferent Times ofTNF Administration on the Relative Growth of 
EAT cells treated with rhTNF-a + Step-down Hyperthermia 3. EAT cells at 1.5xlO^ 
cells/ml, after seeded for 20 hours at 37°C, were treated with rhTNF-a andA)r heated at 
43°C for 1 hours and then at 40°C for 24 hour. Some cells were treated with rhTNF-a 7, 6, 
4，and 2 hours before heat (designated by negative numbers) and some were treated with 
rhTNF-a 0，3, and 6 hour(s) after heat (designated by positive numbers). The cells were 
heated with the presence of TNF-a. Viable cells were counted by trypan blue exclusion 
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Fig. 3.3b Effect of Different Times of TNF Administration on the Viability of EAT 
ceIIs treated with rhTNF-a + Step-down Hyperthermia 3. The protocol was similar to 
that described in Figure 3.3a，except the results are expressed as percent viability 
(%Viability). 
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the synergistic effect between TNF and step-down hyperthermia 2 to vanish. The total 
numbers of viable cells that were left after the combined treatments with rhTNF-a added 6 
and 7 hours before heat were about 30% of the untreated cells. Although the results were 
still lower than that of the single treatments, they were not higher than the added value. 
This indicated that a long interval period between TNF and step-down hyperthermia 3 
treatments was not desirable. 
The result for the cytotoxic effect of this combined treatment is shown in Fig. 3.3b. 
Again, adding rhTNF-a 4 hours before heating was found to be the best sequence of TNF + 
step-down hyperthermia 3 treatment and it was most cytotoxic to EAT cells. More than 
94% of cells were killed after this treatment. Survival increased as TNF administration was 
delayed. About 25% of EAT cells survived when TNF administration time was t=-2 hour; 
about 35% of cells survived when rhTNF-a was administered at or after heat. Although the 
cytotoxic effect of this combined treatment was milder when rhTNF-a was administered at 
times other than t=-4 hour, the effect was stronger than the additive result of the single 
treatments. The result showed that changing the sequence between heat and TNF did not 
damage the synergism between the two individual anti-tumor treatments, but weakened the 
killing ability of the combined treatment. 
3.1.2 Optimal Sequence of Treatments on Human Leukemia cells HL-60: 
3.1.2.1 TNF + Fixed-temperature Hyperthermia: 
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The effect ofdifFerent times ofTNF administration ofcombined treatment ofTNF + 
fixed-temperature hyperthermia on human leukemia HL-60 cells was examined in this 
section. As shown in Fig. 3.4a，suppression of growth was highest for the HL-60 cells 
treated with TNF-a 4 hours before the start of fixed-temperature hyperthermia. The 
number ofviable cell was about 24% of that of the untreated cell. A general increase of 
relative growth was observed as TNF-a was administered at later time points. Less than 
34% ofsuppression was seen with TNF-a administered 3 hours after heating. Suppression 
ofgrowth was minimal when TNF-a was administered 6 hours after initiation ofheat. Only 
about 13% of suppression was achieved, which was not significantly different from the 
untreated cells (p>0.05). Relative growth were less than 50% for all other combined 
treatments ofTNF + fixed-temperature hyperthermia, but a sudden rise ofgrowth could be 
observed for treatments with fixed-temperature hyperthermia prior to TNF treatment. If 
additive effect was assumed to exist for TNF + fixed-temperature hyperthermia treatment. 
73.87o/o ofpercent of control should be obtained (97.72% x 75.59%). Treatment with TNF 
administration time t=6 hour was found to produce higher relative growth than the 
calculated figure, indicating that with this late TNF administration time as related to fixed-
temperature hyperthermia treatment, the effect of fixed-temperature hyperthermia was 
weakened. The result obtained for treatment with TNF administration t=3 hour was similar 
to the calculated figure, showing that the effect of the two individual treatments were not 
eliminated but synergism did not exist, whereas combined treatments with rhTNF-a prior to 
fixed-temperature hyperthermia produced synergistic effect. Similar to the result ofrelative 
61 
120 ^ 
100 - i T 
8 0 -
"3 h 
I 6。 - • 门 
^ 丁 40 - r h p L pL | 
丁 f~*~] . 
T 
20 - 门 
° � o \ ^ ^ , 'b > > ^ > ^ � ^ 
cf ^ ^ <^2> < ^ TNF Administration Time (h from init. of 43®C) 
Fig. 3.4a Effect ofDifTerent Times of TNF Administration on the Relative Growth of 
HL-60 cells treated with rhTNF-a + Fixed-temperature Hyperthermia . HL-60 cells at 
5.0xl0^ cells/ml, after seeded for 20 hours at 37�C, were treated with rhTNF-a and/or 
heated at 43�C for 3 hours. Some cells were treated with rhTNF-a 6’ 4, 3, 2，and 1 hour(s) 
before heat (designated by negative numbers) and some were treated with rhTNF-a 0，3， 
and 6 hour(s) after heat (designated by positive numbers). The cells were heated with the 
presence of TNF-a. The cells were incubated at 37°C for 24 hours after heat treatment. 
Viable cells were counted by trypan blue exclusion method. The results are expressed as 
relative growth (%Control). 
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Fig. 3.4b Effect ofDifFerent Times ofTNF Administration on the Viability of HL-60 
cells treated with rhTNF-a + Fixed-temperature Hyperthermia • The protocol was 
similar to that described in Figure 3.4a，except the results are expressed as percent viability 
(%Viability). 
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growth, highest cytotoxic effect was found with treatment with TNF-a administered 4 
hours before initiation of heat (50.6%) O i^g. 3.4b). This effect diminishes gradually as 
TNF-a was administered at later time points, and was eliminated when TNF-a was 
administered 6 hours after initiation of43"C. More than 97% oftumor ceUs survived after 
that treatment. In addition, cytotoxic effect oftreatment with TNF-a administered 3 hours 
after heat was shown to be insignificantly different from that with fixed-temperature 
hyperthermia only. This indicates that although this treatment significantly killed HL-60, its 
cytotoxicity might be totally exerted by hyperthermia. The role of TNF-a in cell killing 
might be negligible. 
3.1.2.2 TNF + Step-Down Hyperthermia 2: 
The effect ofdifFerent TNF administration time on TNF + step-down hyperthermia 2 
treatment is shown in Fig. 3.5. Figure 3.5a showed the effect on the growth suppression. 
Six hours before step-down hyperthermia 2 was found to be the best TNF administration 
time. Growth of HL-60 cells was suppressed to about 50% of control, which was the 
highest growth suppression effect found for this combined treatment. Treatments with 
rhTNF-a administration before heat resulted in less cell growth. Effect oftreatment with 
these TNF administration times all seemed to be synergistic. Less than 85% ofgrowth was 
resulted. On the other hand, for treatments with step-down hyperthermia 2 applied before 
rhTNF-a, the growth was almost unaffected. More than 95% of relative growth were 
obtained, showing that the treatment of TNF + step-downhyperthermia2 werenot 
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Fig. 3.5a Effect ofDifferent Times ofTNF Administration on the Relative Growth of 
HL-60 cells treated with rhTNF-a + Step-down Hyperthermia 2. HL-60 cells at 
5.0xlO^ cells/ml, after seeded for 20 hours at 37�C’ were treated with rhTNF-a and/or 
heated at 43°C for 2 hours and then at 40�C for 1 hour. Some cells were treated with 
rhTNF-a 6, 4，3，and 2 hours before heat (designated by negative numbers) and some were 
treated with rhTNF-a 0, 3，and 6 hour(s) after heat (designated by positive numbers). The 
cells were heated with the presence of TNF-a. The cells were incubated at 37�C for 24 
hours after heat treatment. Viable cells were counted by trypan blue exclusion method. The 
results are expressed as relative growth (%Control). 
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Fig. 3.5b Effect of Different Times of TNF Administration on the Viability of HL-60 
cells treated with rhTNF-a + Step-down Hyperthermia 2. The protocol was similar to 
that described in Figure 3.5a，except the results are expressed as percent viabilitv 
(%Viability). � 
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effective in suppressing the growth of HL-60 when rhTNF-a was administered after heat 
treatment. 
Effect ofdifFerent TNF administration time on the cytotoxicity is shown in Fig. 3.5b. 
Similar to the result of relative growth, highest cytotoxicity was achieved by adding rhTNF-
oc 6 hours before step-down hyperthermia 2 treatment. Viabilities were all very high for 
this treatment with other TNF administration times; however a slight difference could be 
observed. TNF + step-down hyperthermia 2 treatment with rhTNF-a applied before heat 
produced viability lower than 95%, whereas that with rhTNF-a applied after heat resulted 
in viability higher than 95%. The result showed that TNF + step-down hyperthermia 2 
treatment was not effective in killing HL-60 except when rhTNF-a was administered 6 
hours before step-down hyperthermia 2. 
3.1.2.3 TNF + Step-Down Hyperthermia 3: 
Result of sequence determination of TNF-a and step-down hyperthermia 3 on HL-
60 is shown in Fig. 3.6. Suppression of growth was highest for the cells treated with TNF-
a 4 hours before the start of step-down hyperthermia 3. The number ofviable cells after 
treatment was less than 16% of that of the control cells without treatment. A general rise in 
relative growth was associated with the delay ofTNF-a administration time. When TNF-a 
was administered after heat treatment, the growth suppression effect was minimal despite 
the growth was suppressed to 60%. Although the growth of all treated cells, regardless 
when TNF-a was administered, was significantly lower than the control cells (p>0.005), the 
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differences between the growth resulted from TNF-a after heat treatment, and that with 
step-down hyperthermia 3 treatment only were not significant (p>0.05), indicating that the 
effect of TNF-a was concealed. The effect of growth suppression might solely come from 
step-down hyperthermia 3. This only occurred to treatment with step-down hyperthermia 3 
prior to rhTNF-a treatment. When rhTNF-a was administered to cells before heat, the 
result showed higher growth suppression than either single treatment or addition of the two 
(97.72% X 60.42% = 59.04%), indicating that synergistic effect existed in this combined 
treatment when rhTNF-a was added before heat. However, when rhTNF-a was added 6 
hours before hyperthermia, the relative growth rose to about 60%, which was not 
significantly different from the additive effect of the two single treatments. This might be an 
indication that 6 hours between the two treatments might be too long for synergistic effect 
to occur. 
Cytotoxicity of the treatment on the cells is shown in Fig. 3.6b. The lowest % 
viability, about 32% was found on the culture treated with TNF-a 4 hours before initiation 
of 43°C ^"ig. 2b). Again, percent of viability rose with the delay of TNF administration 
time, and cytotoxic effect of treatments with rhTNF-a follows heat were insignificantly 
different from step-down hyperthermia 3 (p>0.05), showing that step-down hyperthermia 3 
might be the sole player in cell killing in the reversed-sequence treatment. On the other 
hand, treatments with rhTNF-a added before step-down hyperthermia 3 produced lower 
viability than either single treatments. The viability of EAT cells treated with rhTNF-a 
prior to step-down hyperthermia 3 treatment were much lower than the additive result of 
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Fig. 3.6a Effect ofDifFerent Times of TNF Administration on the Relative Growth of 
HL-60 cells treated with rhTNF-a + Step-down Hyperthermia 3. HL-60 cells at 
5.0xl0^ cells/ml, after seeded for 20 hours at 37T, were treated with rhTNF-a and/or 
heated at 43°C for 1 hours and then at 40°C for 24 hour. Some cells were treated with 
rhTNF-a 6, 4，3, 2, and 1 hours before heat (designated by negative numbers) and some 
were treated with rhTNF-a 0，1，3, and 6 hour(s) after heat (designated by positive 
numbers). The cells were heated with the presence ofTNF-a. Viable cells were counted by 
trypan blue exclusion method. The results are expressed as relative growth (%Control). 
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Fig. 3.6b Effect ofDifferent Times of TNF Administration on the Viability of HL-60 
cells treated with rhTNF-a + Step-down Hyperthermia 3. The protocol was similar to 
that described in Figure 3.6a，except the results are expressed as percent viability 
(%Viability). 
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the two single treatments. This result supported the argument that synergism existed for 
TNF + step-down hyperthermia 3 treatment on HL-60 cells when heat was applied after 
rhTNF-a, and that the two individual treatments cooperated synergistically to suppress 
growth and kill HL-60 cells at the same time. 
The above experiments conclude that for all of the three combined treatments, TNF-
a + fixed-temperature hyperthermia, TNF + step-down hyperthermia 2, or TNF + step-
down hyperthermia 3, rhTNF-a must be administered before heat treatment in order to 
achieve maximum effect. Weaker growth suppression and cytotoxic effect were found with 
delaying TNF administration time. In most cases, when rhTNF-a was administered after 
heat, synergistic effects were eliminated, or sometimes protective effect against each other 
might be resulted. Four hours before the initiation of heat was found to be the best TNF 
administration time for TNF + fixed-temperature hyperthermia and TNF + step-down 
hyperthermia 3 for both human and murine cell lines. Administration of rhTNF-a 6 hours 
before step-down hyperthermia 2 was the optimal sequence of treatment for TNF + step-
down hyperthermia 2. These optimal sequence of treatments were used in the comparison 
of treatments' efficacy in the next section. 
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3.2 Comparison of Effectiveness of Treatments: 
This section will examine the effectiveness of various treatments including single 
treatments, such as TNF, fixed-temperature hyperthermia, step-down hyperthermia 2, and 
step-down hyperthermia 3; and combined treatments, such as TNF + fixed-temperature 
hyperthermia, TNF + step-down hyperthermia 1’ TNF + step-down hyperthermia 2, and 
TNF + step-down hyperthermia 3. Two combined treatments, TNF + 43"C-heat for lhour 
and TNF + 40°C-heat for 24 hours, were also conducted as reference. The most effective 
treatment would be found out for both EAT cells and HL-60 cells. 
3.2.1 Effectiveness ofVarious treatments on EAT cells: 
Figure 3.7a showed the relative growth of EAT cells resulted from various 
treatments. Growth suppression effect of single treatments were very mild except for the 
prolonged heat treatment - step-down hyperthermia 3. Less than 25% of growth 
suppression was achieved by TNF, fixed-temperature hyperthermia, and step-down 
hyperthermia 2. Higher growth suppression was achieved by step-down hyperthermia 3. 
The cell density after this treatment was only about 22% of the control. However, when 
these single treatments were combined, the growth suppression effect was strongly 
enhanced. The most effective growth suppression was achieved by TNF + fixed-
temperature hyperthermia. Less than 10% of cell density as compared to control was 
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resulted. But when the heating period was shortened, that is TNF + heating at 43°C for 1 
hour，the growth suppression effect was much less severe. About 74% ofrelative growth 
was achieved. The result indicated that for the combined treatment with TNF + fixed-
temperature hyperthermia, the heating period had to be 3 hours. Combined treatment with 
TNF + step-down hyperthermia 3 was also very effective in suppressing EAT cells' growth. 
The cell density after this treatment was 87% less than the untreated cells. However, when 
the heating period was shortened, combined treatments with step-down hyperthermia were 
not very effective in suppressing EAT growth. Cell density was remained to be 80% of 
control after treated with TNF + step-down hyperthermia 1. Even with 2 hours heat at 
430Q growth suppression was still less than 50%. The result suggested that in order for the 
combined treatment with step-down hyperthermia to be effective, the heating period must 
be prolonged. In addition, a similar growth suppression level achieved by TNF + heating at 
40�C for 24 hours (T/40(24)) was observed. Cell density of 8.7% was resulted after this 
treatment. This result might be an indication that much of the growth suppression effect 
were resulted from the step with heating at 40°C for 24 hours. Moreover, as mentioned 
before，the growth suppression effect exerted by TNF + heating at 43�C for 1 hour was very 
mild，further supported the argument that the severe growth suppression effect ofthis step-
down hyperthermia came from the prolonged heating at 40°C. 
Cytotoxic effect of various treatments were compared in Fig. 3.7b. Ail the single 
treatments showed minimal cytotoxic effect. Over 78% ofEAT cells survived after these 
single treatments. However, when these treatments were combined, viability dropped to 
26%-36%. Again, TNF + fixed-temperature hyperthermia produced the lowest survival 
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rate, only about 26% of EAT survived the treatment. TNF + step-down hyperthermia 3 
treatment was also effective. More than 60% of cells were killed. However, when step-
down hyperthermia was with short heating period, as in the cases of TNF + step-down 
hyperthermia 1 and step-down hyperthermia 2，the combined treatment became less 
cytotoxic. TNP + step-down hyperthermia 1 could only kill less than 5% of EAT cells; 
whereas TNF + step-down hyperthermia 2 killed only about 40% of ceUs. The result 
suggested that combined treatment with step-down hyperthermia required a prolonged 
heating period to be effective in killing EAT cells. Additionally TNF + heating at 40�C for 
24 hours resulted in a similar level of cytotoxicity. About 28% of viabiUty was resulted, 
indicating that much of the cytotoxic effect of the TNF + step-down hyperthermia 3 
treatment was contributed by the prolonged heat treatment at 40°C. Furthermore, the 
cytotoxic effect of TNF + heating at 43�C for 1 hour was minimal. This treatment only 
killed about 5% ofEAT cells. This result suggested that TNF + heating at 43°C for 1 hour 
did not contribute much to the cytotoxicity ofTNF + step-down hyperthermia 3. The step 
with heating at 40°C for 24 hours was the major player in killing EAT cells. 
3.2.2 Synergistic Effect between rhTNF-a and Hyperthermia on EAT cells: 
Great enhancement in the effectiveness of the treatments was observed when the 
single treatments were combined, and synergism is hence suggested. Table 3.1 showed the 
relative growth and viability of the single treatments, the expected additive result, and the 
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Fig. 3.7a Relative Growth of EAT Cells after Various Treatments. EAT cells at 
1.5xlO^ cells/ml were seeded for 20 hours at 37°C before treatments. The treatments were 
as follows: Control = untreated cells, TNP = TNF treatment, Hyperthermia = fixed-
temperature hyperthermia, SDH2 = step-down hyperthermia 2, SDH3 = step-down 
hyperthermia 3，TNF/43(1) = TNF + heating at 43°C for 1 hour, TM7Hyp = TNF + fixed 
temperature hyperthermia, TNF/40(24), TNF + heating at 40�C for 24 hours, TNF/SDH1 = 
TNF + step-down hyperthermia 1，TNF/SDH2 = TNF + step-down hyperthermia 2, 
TNF/SDH3 = TNF + step-down hyperthermia 3. Treatments were done as described in 
Materials and Methods. The optimal treatment sequence for each combined treatment 
determined in the previous sections was used for the combined treatments. Viable cells 
were counted by trypan blue exclusion method. The results are expressed as relative 
growth (%Control). 
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Fig. 3.7b Viability ofEAT Cells after Various Treatments. The protocol was similar to 
that described in Fig. 3.7a，except the results are expressed as percent viability (%Viability). 
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experimental result for comparison. If the effect ofthe combined treatments were only an 
addition of the two single treatments, the relative growth resulted from TNF + fixed-
temperature hyperthermia, TNF + step-down hyperthermia 2, and TNF + step-down 
hyperthermia 3 treatments should be 69.67%, 72.45%, and 17.25%, respectively. These 
calculated results were compared to the experimental results. 8.37% of control was 
obtained for TNF + fixed-temperature hyperthermia treatment. The big difference between 
this experimental result and the expected result clearly stated that synergism existed 
between TNF and fixed-temperature hyperthermia. A 16% difference was found for TNF + 
step-down hyperthermia 2 treatment, also indicating the existence of synergism in 
suppressing the growth ofEAT cells. The experimental percent ofcontrol for TNF + step-
down hyperthermia 3 was 12.85%, which was not far away from the calculated result, 
suggesting that the enhancement in effectiveness of the combined treatment might solely 
due to addition of the effect ofthe two single treatments. 
The expected viability ofTNF + fixed-temperature hyperthermia, TNF + step-down 
hyperthermia 2, and TNF + step-down hyperthermia 3 were also calculated with the 
assumption that solely additive effect existed for the combined treatments, and they were 
76.460/0，76.60%, and 64.73%, respectively. A big difference between the experimental 
result of TNF + fixed-temperature hyperthermia and the calculated result was noted. 
Similarly, the experimental percent viability of TNF + step-down hyperthermia 3 was also 
much lower than the calculated result. Both of these suggested synergism existed between 
















































































































































































































3.2.3 Decrease of Relative Growth and Viability with Time: 
There was a general observation that EAT cells was not killed instantly after the 
treatments. They died gradually after the treatments and reached at a very low point after a 
long period of time. This section examined the change of relative growth and viability of 
EAT cells with time. 
3.2.3.1 TNF + Fixed-temperature Hyperthermia: 
As indicated in Fig. 3.8, the viability of EAT cells did not drop at the early stage 
after the TNF + fixed-temperature hyperthermia treatment. Even after 18 hours, the 
viability remained above 70%. On the other hand, growth suppression started at early 
stage. The growth was suppressed to about 85% right after the treatment. Furthermore, 
after 18 hours, the cell density was only 40% of control. Both relative growth and viability 
continued to drop to a very low level after 24 hours. 
3.2.3.2 TNF + Step-down Hyperthermia 2: 
The change of relative growth and viability with time for combined treatment with 
short heating time of step-down hyperthermia was represented in Fig. 3.9. Both relative 
growth and viability increased after a brief drop. In spite ofthat, an earlier onset ofgrowth 
suppression than cytotoxicity was observed. The cell density after this treatment was 80% 
of control immediately after treatment, and about 55% of control 2 hours after treatment. 
The growth suppression effect did not persist long, the cells started to proliferate after 2 
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Fig. 3.8 Change of Relative Growth and Viability of EAT cells after TNF + Fixed-
temperature Hyperthermia Treatment, (a) Relative growth ofEAT cells, and (b) Percent 
viability of EAT cells after treatment. EAT cells at 1.5xlO^ cells/ml of EAT cells, after 
seeded for 20 hours at 37�C, were treated with rhTNF-a and then incubated at 37T for 4 
hours. The cells were then heated at 43�C for 3 hours with the presence ofTNF-a. Cells 
were incubated at 37°C afterwards and collected at different time intervals after heat 
treatment. Viable cells were counted by trypan blue exclusion method. 
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Fig. 3.9 Change of Relative Growth and Viability of EAT cells after TNF + Step-
down Hyperthermia 2 Treatment, (a) Relative growth of EAT cells, and (b) Percent 
viability of EAT cells after treatment. 1.5xlO' cells/ml of EAT cells, after seeded for 20 
hours at 37°C, were treated with rhTNF-a and then incubated at 37°C for 6 hours. The 
cells were then heated with the presence of TNF-a at 43°C for 2 hours and then transferred 
to 40°C for 1 hour. After treatment, cells were incubated at 37�C and collected at different 
time intervals. Viable cells were counted by trypan blue exclusion method. 
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hours and reached at about 80% after 24 hours. The decrease of viability was minimal for 
this treatment. The drop did not even reach 20% before rebounding at 15 hours after 
treatment. 
3.2.3.3 TNF + Step-down Hvperthermia3: 
Drastic drop in relative growth and viability were noted for TNF + step-down 
hyperthermia 3 treatment as compared to other treatment on EAT cells OFig. 3.10). Again, 
the growth suppression was found to start earlier than the cytotoxic effect. The cell density 
was more than 30% lower than the untreated cells right after the treatment, and dropped to 
about 10% after 14 hours. It then stared to level off. About 90% ofviable cell could still 
be found 4 hours after treatment; but then it decreased drastically and after 18 hours, less 
then 20% ofviability was observed, at which point the decrease became stable. 
3.2.4 Comparison of Effectiveness of Various Treatments on HL-60 cells: 
The effect of various treatments on the human cell line was shown in Fig. 3.11.. 
Treatment with rhTNF-a only showed minimal effect on the growth suppression of HL-60 
cells. The cell density after TNF treatment was only 2% less than the untreated cells. 
Fixed-temperature hyperthermia, as well as the step-down hyperthermia 3 could suppress 
the cell growth to 76% and 60%, respectively; however, step-down hyperthermia with short 
heating duration, as in the case of step-down hyperthermia 2, did not have any growth 
suppression effect on HL-60 cells. Enhancement of growth suppression effect were 
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Fig. 3.10 Change of Relative Growth and Viability of EAT cells after TNF + Step-
down Hyperthermia 3 Treatment, (a) Relative growth of EAT ceUs, and ¢ ) Percent 
viability of EAT cells after treatment. EAT cells at 1.5xlO^ cells/ml, after seeded for 20 
hours at 37X, were treated with rhTNF-a and then incubated at 37�C for 4 hours. The 
cells were then heated with the presence ofTNF-a at 43°C for 1 hours and then transferred 
to 40°C for 24 hour. Cells were collected at different time interval after the initiation of 
40�C. Viable cells were counted by trypan blue exclusion method. 
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observed in combined treatments. The highest growth suppression was achieved by TNF + 
fixed-temperature hyperthermia treatment. Only 23.4% of relative growth was resulted. 
TNF + step-down hyperthemia 3 was found to suppress HL-60 cell growth to about 50%. 
A similar level ofgrowth suppression was observed for TNF + heating at 40�C for 24 hours. 
In addition, the treatment with TNF + heating at 43�C for 1 hour only produced minimal 
growth suppression effect. Slightly more than 6% of growth suppression was observed. 
Both ofthese data suggested that much of the growth suppression effect was contributed by 
the prolonged heating step at 40�C. The roles ofrhTNF-a and heating at 43�C for 1 hour 
were less important. On the other hand, TNF + step-down hyperthermia 2 could also 
produce a similar growth suppression effect as the TNF + step-down hyperthermia 3. This 
might be an indication that combined treatment with step-down hyperthermia with short 
heating duration might also achieve a strong growth suppression effect as TNF + step-down 
hyperthermia 3,which had a long heating duration. However, when the high temperature 
step of the step-down hyperthermia was shortened to 1 hour in the short-heating-duration 
step-down hyperthermia, as in the case ofTNF + step-down hyperthermia 1, the growth 
suppression effect was reduced. The result showed that the additional 1 hour at 43°C heat 
treatment compensated for the long duration ofheat treatment at 40°C. 
Cytotoxicity ofvarious treatments is shown in Fig. 3.11b. Single treatments, except 
for step-down hyperthermia 3, were found to have almost no cytotoxic effect on HL-60 
cells. All ofthem produced less than 5% cytotoxicity on the cells. Step-down hyperthemia 
3 resulted in 82.6% of viability, which was the highest cytotoxicity achieved among all 
single treatments. Viability dropped when the single treatments were combined. The 
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Fie 3 11a Relative Growth of HL-60 Cells after Various Treatments. HL-60 cells at 
0^；10^  cells/ml were seeded for 20 hours at 37�C before treatments. Thetreatments were 
as follows: Control = untreated cells, TNF = TNF treatment H^erthermia = fixed-
Lpera tu re hyperthermia, SDH2 = step-down hyperthermia ^ SDH3 = step-down 
h J ^ ^ h : a 3 TNF/43(1) = TNF + heating at 43�C for 1 hour, TNF/Hyp = TNF + fixed 
S S = r h i e : = : ) T N F M _ )， T ^ + heating at 桃 for 24 hours, TNF/SDH1 = 
TNF + step-down hyperthermia 1，TNF/SDH2 = TNF + step-down hyperthenma 2， 
TNF/SDH3 = TNF + step-down hyperthermia 3. Treatments were done as descnbed in 
Materials and Methods. The optimal treatment sequence for each combined treatment 
determined in the previous sections was used for the combined treatments. Viable cells were 
counted by trypm blue exclusion method. The results are expressed as relative growth 
(%Control). 
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Fig 3 11b Viability ofHL-60 Cells after Various Treatments. The protocol was similar 
to that described in Fig. 3.11a，except the results are expressed as percent viability (%Viability). 
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highest cytotoxicity was achieved by TNF + fixed-temperature hyperthermia. About 40% 
ofcells were killed after this treatment. TNF + step-down hyperthermia 3 resulted in about 
24% cell death. Similar cytotoxicity level was achieved by TNF + heating at 40�C for 24 
hours, showing that much ofthe cytotoxic effect ofTNF + step-down hyperthermia 3 was 
contributed by the step with prolonged heating at 40°C for 24 hours. The low cytotoxicity 
resulted from TNF + heating at 43°C for 1 hour also suggested that TNF and heating at 
43°C was not very effective and the step with heating at 40°C for 24 hours was the major 
player in cell killing. Similar to the growth suppression effect on HL-60 cells, TNF + step-
down hyperthermia 2 could also produce a similar cytotoxic effect as TNF + step-down 
hyperthermia 3，indicating that combined treatment with step-down hyperthermia could also 
be effective even ifthe heating period was short. However, TNF + step-down hyperthermia 
1 was found to cause less than 7% cell death. The result showed that the additional 20% 
cell death caused by TNF + step-down hyperthermia 2, as compared to TNF + step-down 
hyperthermia 1，was due to the additional one-hour heating at 43�C，and this additional one-
hour heating could be a replacement for the prolonged heating 40°C for 24 hours. 
3.2.5 Synergistic Effect between rhTNF-a and Hyperthermia on HL-60 cells: 
The expected additive effect was calculated and presented in Table 3.2. With the 
assumption that the enhanced effectiveness of the combined treatments were solely due to 
the addition of effect of 2 treatments, the relative growth resulted from the TNF + fixed-
temperature hyperthermia, TNF + step-down hyperthermia 2, and TNF + step-down 
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hyperthermia 3 treatments should be 73.87%, 101.15% and 59.04%, respectively. When 
these figures were compared to the experimental results, a big difference could be observed. 
23.37% of relative growth was obtained from the TNF + fixed-temperature hyperthermia 
treatment experimentally. This 3-fold difference between the experimental result and the 
calculated result strongly suggested synergism between rhTNF-a and fixed-temperature 
hyperthermia. Since step-down hyperthermia 2 by itself did not exert any growth 
suppression effect on HL-60 cells, it was not expected to cause any decrease in growth 
when it was combined with TNF treatment. If the two treatments did not cooperate 
synergistically, a combination of the two treatments would only produce a growth 
suppression solely due to rhTNF-a. The experimental result showed the opposite. The cell 
density dropped to 49.47% of control after TNF + step-down hyperthermia 2 treatment, 
suggesting that synergistic effect was involved. Less than 10% difference was found 
between the experimental relative growth and the calculated result for TNF + step-down 
hyperthermia 3 treatment, suggesting that the decrease of growth might solely due to 
additive effect of the two agents. 
Synergism in cytotoxicity was also investigated. The expected additive result were 
calculated to be 92.52%, 95.13%, and 80.33%, respectively, for TNF + fixed-temperature 
hyperthermia, TNF + step-down hyperthermia 2，and step-down hyperthermia 3 treatments. 
Experimental viability of TNF + fixed-temperature hyperthermia and TNF + step-down 
hyperthermia treatments were found to be 33% and 20% lower than the calculated results, 
clearly indicated the existence of synergism between TNF and fixed-temperature 






















































































































































































































difference between calculated result and the experimental result was found for TNF + step-
down hyperthermia 3 treatment, showing that only additive effect was involved. 
3.2.6 Change ofRelative Growth and Viability ofHL-60 with Time: 
Similar to the effect on EAT cells, the cytostatic and cytotoxic effects of the 
combined treatments were found to be less for a prolonged period after treatment. Using 
the optimal sequence of treatment, the change of relative growth and viability were 
monitored over 24 hours and is presented in this section. ' 
3.2.6.1 TNF + Fixed-temperature Hyperthermia: 
Figure 3.12 clearly showed that the cytostatic effect of TNF + fixed-temperature 
hyperthermia was more severe than the cytotoxic effect, and its onset was earlier than that 
of the cytotoxicity. The cell density was already less than 10% lower than the control when 
measured right after the treatment and dropped to 20% of control after 18 hours, at which 
the suppression effect seemed to have stopped. On the other hand, viability did not 
decrease at early stage after treatment. 70% of cells was still alive even after 14 hours. At 
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Fig. 3.12 Change ofRelative Growth and Viability of HL-60 ceUs after TNF + Fixed-
temperature Hyperthermia Treatment, (a) Relative growth of HL-60 ceUs, and ¢ ) 
Viability ofHL-60 cells after treatment. HL-60 cells at 5.0xl0^ cells/ml, after seeded for 20 
hours at 37°C, were treated with rhTNF-a and then incubated at 37°C for 4 hours. The 
cells were then heated at 43�C for 3 hours with the presence of TNF-a. Cells were 
incubated at 37°C afterwards and collected at different time intervals after heat treatment. 
Viable cells were counted by trypan blue exclusion method. 
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3.2.6.2 TNF + Step-down Hyperthermia 2: 
TNF + step-down hyperthermia 2 seemed to have stronger cytostatic effect than 
cytotoxic effect ^"ig. 3.13). The growth suppression effect did not start until the end of 
heat treatment. The cell density was the same as control at 0 hour after treatment and 
dropped for 10% at 2 hours. The relative growth continued to decrease gradually over 24 
hours. The decrease of viability was minimal, and started to rebound after a brief drop at 18 
hours. 
3.2.6.3 TNP + Step-down hyperthermia 3: ^ 
An earlier onset of growth suppression effect than cytotoxicity was again observed 
OFig. 3.14). The cell density was already 20% less than control when measured after 
heating at 43°C for 1 hour (Fig. 3.14a). It continued to decrease contantly over 24 hours. 
On the other hand, viability remained at over 95% at the first 4 hours of the 40oC heat 
treatment. It continued to decrease at a mild rate until after 18 hours, at which point the 
viability dropped drastically for 70%. 
In the above experiments, TNF + fixed-temperature hyperthermia was found to be 
the most effective combined treatment against both EAT and HL-60 cells. Highest growth 
suppression and cytotoxicity were found among ail treatments involving TNF and/or heat, 
and synergism between the two individual treatments to greatly enhance the cytostaticity 
and cytotoxicity was noted. TNF + step-down hyperthermia 3 was also found to be 
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effective but prolonged heating was necessary. TNF + step-down hyperthermia 2 was 
effective against HL-60 cells, but not EAT cells. 
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Fig. 3.13 Change of Relative Growth and Viability of HL-60 cells after TNF + Step-
down Hyperthermia 2 Treatment, (a) Relative growth ofHL-60 cells, and (b) ViabiUty of 
HL-60 cells after treatment. HL-60 cells at 5.0xl0^ cells/ml, after seeded for 20 hours at 
37°C, were treated with rhTNF-a and then incubated at 37�C for 6 hours. The cells were 
then heated with the presence ofTNF-a at 43�C for 2 hours and then transferred to 40°C 
for 1 hour. After treatment, ceils were incubated at 37�C and collected at different time 
intervals. Viable cells were counted by trypan blue exclusion method. 
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Fig. 3.14 Change of Relative Growth and Viability of HL-60 cells after TNF + Step-
down Hyperthermia 3 Treatment, (a) Relative growth ofHL-60 cells, and 0?) Viability of 
HL-60 cells after treatment. HL-60 cells at 5.0xl0^ cells/ml, after seeded for 20 hours at 
37°C，were treated with rhTNF-a and then incubated at 37�C for 4 hours. The cells were 
then heated with the presence of TNF-a at 43°C for 1 hours and then transferred to 40�C 
for 24 hour. Cells were collected at different time interval after the initiation of 40°C. 
Viable cells were counted by trypan blue exclusion method. 
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3.3 Cell Death Pathway: 
Investigation in the cell kill mechanism ofthe combined treatments would be easier 
if the cell death pathway is known. This section would examined whether the cell death 
involved apoptosis after the combined treatments. The time at which apoptosis occurred 
would also be investigated. 
3.3.1 Experiments on Ehrlich Ascites Tumor OEAT) Cells: 
DNA electrophoresis of cells treated with TNF + fixed-temperature hyperthermia, 
TNF + step-down hyperthermia 2，and TNF + step-down hyperthermia 3 were done. 
Figure 3.15 showed the DNA ofcells collected at different times after treated with TNF + 
fixed-temperature hyperthermia. No DNA ladder pattem was observed for cells collected at 
any time, showing that apoptosis was not involved in the cell killing of this treatment. 
Figure 3.16 and 3.17 showed the result of DNA electrophoresis of cells collected at 
different times after TNF + step-down hyperthermia 2 and TNF + step-down hyperthermia 
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Fig. 3.15 DNA Electrophoresis of EAT CeIIs treated with TNF + Fixed-temperature 
Hyperthermia. EAT cells at 1.5xlO^ cells/ml, after seeded for 20 hours at 37°C, were 
treated with rhTNF-a and incubated at 37�C for 4 hours. The cells were then heated at 
43°C for 3 hours and then incubated at 37�C. Cells were harvested at different time 
intervals after treatment and DNA were extracted and DNA electrophoresis was performed. 
Lane 1 was the 100n base-pair Marker; Lane 2 was the Control cells; Lane 3 was the cells 
harvested at 0 hour after treatment; Lane 4 was cells from 2 hours after treatment; Lane 5 
was cells from 14 hours; Lane 6 was cells from 18 hours; Lane 7 was cells from 20 hours; 
Lane 8 was cells from 22 hours; and Lane 9 was cells from 24 hours. 
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二. 
Fig. 3.16 DNA Electrophoresis of EAT Cells treated with TNF + Step-down 
Hyperthermia 2. EAT cells at 1.5xlO^ cells/ml, after seeded for 20 hours at 37�C, were 
treated with rhTNF-a and incubated at 37�C for 6 hours. The ceUs were then heated at 
43°C for 2 hours and then at 40°C for 1 hour. The cells were then incubated at 37°C. Cells 
were harvested at different time intervals after treatment and the DNA were extracted and 
DNA electrophoresis was performed. Lane 1 was the 100n base-pair Marker; Lane 2 was 
the Control cells; Lane 3 was the cells harvested at 0 hour after treatment; Lane 4 was cells 
from 2 hours after treatment; Lane 5 was cells from 15 hours; Lane 6 was ceUs from 18 
hours; Lane 7 was cells from 20 hours; and Lane 8 was cells from 24 hours. 
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Fig. 3.17 DNA Electrophoresis of EAT Cells treated with TNF + Step-down 
Hyperthermia 3. EAT cells at 1.5xlO^ cells/ml, after seeded for 20 hours at 37°C, were 
treated with rhTNF-a and incubated at 3TC for 4 hours. The cells were then heated at 
43�C for 1 hour and then at 40�C. Cells were harvested at different time intervals after 
treatment and the DNA were extracted and DNA electrophoresis was performed. Lane 1 
was the 100n base-pair Marker; Lane 2 was the Control cells; Lane 3 was the cells 
harvested at 0 hour after treatment; Lane 4 was cells from 4 hours after treatment; Lane 5 
was cells from 14 hours; Lane 6 was cells from 18 hours; Lane 7 was ceUs from 20 hours; 
Lane 8 was cells from 22 hours; and Lane 9 was cells from 24 hours. 
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3.3.2 Experiments on Human Leukemia (HL-60) Cells: 
Figure 3.18, 3.19’ and 3.20 were the results ofDNA electrophoresis ofHL-60 cells 
collected at different times after TNF + fixed-temperature hyperthermia, TNF + step-down 
hyperthermia 2，and TNF + step-down hyperthermia 3, respectively. Clear ladder patterns 
were shown in the cells treated with TNF + fixed-temperature hyperthermia. Ladder 
pattem was found in lane 3, which was cells collected immediately after the treatment, 
indicating that apoptosis start to occur immediately after the treatment. Apoptosis was 
especially obvious in cells collected at 2 hours after treatment, since the pattem was 
especially outstanding in lane 4. Ladder pattem became fade when the cells were collected 
at later time. The result showed that apoptosis occurred at early stage after treatment, but 
at later time, most of the cells were killed via necrosis. On the other hand, neither TNF + 
step-down hyperthermia 2，nor TNP + step-down hyperthermia 3 showed any ladder 
pattem, indicating that HL-60 treated with TNF + step-down hyperthermia 2 and TNF + 




Fig. 3.18 DNA Electrophoresis ofHL-60 Cells treated with TNF + Fixed-temperature 
Hyperthermia. HL-60 cells at 5.0xl0^ cells, after seeded for 20 hours at 37�C, were 
treated with rhTNF-a and incubated at 37°C for 4 hours. The cells were then heated at 
43°C for 3 hours and then incubated at 37°C. Cells were harvested at different time 
intervals after treatment and DNA were extracted and DNA electrophoresis was performed. 
Lane 1 was the 100n base-pair Marker; Lane 2 was the Control cells; Lane 3 was the cells 
harvested at 0 hour after treatment; Lane 4 was cells from 2 hours after treatment; Lane 5 




Fig. 3.16 DNA Electrophoresis of HL-60 Cells treated with TNF + Step-down 
Hyperthermia 2. HL-60 cells at 5.0xl0^ cells/ml, after seeded for 20 hours at 37°C, were 
treated with rhTNF-a and incubated at 37�C for 6 hours. The cells were then heated at 
43°C for 2 hours and then at 40�C for 1 hour. Cells were then incubated at 37�C. Cells 
were harvested at different time intervals after treatment and the DNA were extracted and 
DNA electrophoresis was performed. Lane 1 was the 100n base-pair Marker; Lane 2 was 
the Control cells; Lane 3 was the cells harvested at 0 hour after treatment; Lane 4 was cells 
from 2 hours after treatment; Lane 5 was cells from 14 hours; Lane 6 was cells from 18 
hours; Lane 7 was cells from 20 hours; and Lane 8 was cells from 24 hours. 
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Fig. 3.20 DNA Electrophoresis of HL-60 Cells treated with TNF + Step-down 
Hyperthermia 3. HL-60 cells at 5.0xl0^ cells/ml, after seeded for 20 hours at 37�C，were 
treated with rhTNF-a and incubated at 37�C for 4 hours. The cells were then heated at 
43°C for 1 hour and then at 40°C. Cells were harvested at different time intervals after 
treatment and the DNA were extracted and DNA electrophoresis was performed. Lane 1 
was the 100n base-pair Marker; Lane 2 was the Control cells; Lane 3 was the cells 
harvested at 0 hour after treatment; Lane 4 was cells from 4 hours after treatment; Lane 5 
was cells from 14 hours; Lane 6 was cells from 18 hours; Lane 7 was cells from 20 hours; 
Lane 8 was cells from 22 hours; and Lane 9 was cells from 24 hours. 
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3.4 Experiment on Normal Cell: 
To design if a treatment is favorable in cancer treatment, its effectiveness should not 
be the sole criteria that is under consideration. Its harmfiil effect against normal cell must 
also be considered. The effect of the combined treatments on the normal human coronary 
artery endothelial cells ^iCAEC) was therefore examined. The relative growth ofHCAEC 
after various treatments is shown in Fig. 3.21. Treatments involved fixed-temperature 
hyperthermia were shown to be harmless to the normal cells. The relative growth of 
HCAEC did not decrease after treated with fixed-temperature hyperthermia or TNF + 
fixed-temperature hyperthermia. Step-down hyperthermia with short heating duration was 
also found to be harmless. The relative growth of the cells after step-down hyperthermia 2 
was almost the same as the untreated cells. Even when this treatment was combined with 
rhTNF-a, the relative growth had only dropped for 20%. However, when the cells were 
treated with prolonged heat treatment, as in the cases of step-down hyperthermia 3 and 
TNF + step-down hyperthermia 3, the cell density dropped. Step-down hyperthermia 3 
alone could cause a 40% decrease in relative growth. When combined with rhlNF^x, the 
relative growth dropped to less than 30%. Such a drastic drop was clearly undesirable. 
TNF + fixed-temperature hyperthermia was found to be the most effective combined 
treatment with least harmful effect on the normal cell. Apoptosis was found in HL-60 cells 
after this treatment. TNF + step-down hyperthermia 2 and TNF + step-down hyperthermia 
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Fig. 3.21 Effect of Various Treatments on Normal HCAEC Cells. HCAEC cells at 
2.0xl0^ were seeded for 20 hours at 37�C before treatments. Control = untreated cells; 
TNF only = TNF treatment; Hyperthermia = fixed-temperature; SDH2 = step-down 
hyperthermia 2 treatment; SDH3 = step-down hyperthermia 3; T/H = TNF + fixed-
temperature hyperthermia; T/SDH2 = TNF + step-down hyperthermia 2; T/SDH3 = TNF + 
step-down hyperthermia 3. Treatments were done as described in Fig. 3.7a. 
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3 were also effective; however, the detrimental effect on normal cells was very severe, 
especially with TNF + step-down hyperthermia 3. TNF + fixed-temperature hyperthermia 
was thus found to be the most favorable combined treatment among the four treatments 
(TNF + fixed-temperature hyperthermia, TNF + step-down hyperthermia 1, TNF + step-
down hyperthermia 2, and TNF + step-down hyperthermia 3) against EAT and HL-60 cells 
in vitro. 
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3.5 Effect of TNF + Fixed-temperature Hyperthermia on the Cell Cycle 
Progression: 
A great enhancement in the effectiveness was observed when TNF treatment was 
combined with fixed-temperature hyperthermia. Synergism between the two individual 
treatments was strongly suggested. Such cooperation might be related to shift in ceU cycle 
progression. This section would examine the change of fraction of cells in different phases 
of cell cycle in relation to different TNF administration time. The effect ofrhTNF-a on this 
change would also be examined. 
3.5.1 Different Times of TNF Administration and Distribution of EAT cells in cell 
cycle: 
Distribution ofEAT cells in different phases of cell cycle were shown in Fig. 3.22. 
X-axis represents the intensity of light emitted from each single cell detected by FL2 
detector. Cells emitted about 400 units of light intensity represented the cells at G0/G1 
phase. The peak shown at around 760 units oflight intensity represented the cells at G2y^ 
phase, at which the cells should have doubled amount of DNA. Cells between the two 
peaks were cells at the S phase. Cells shown before the first peak were cells with less DNA. 
These cells probably had fragmented DNA, which might be due to either necrosis or 
apoptosis, and the DNA were leaked out during fixing in 70% ethanol overnight. Figure 
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3.22a showed the distribution of control cells. A large portion of cells were at G0/G1 
phase. Only a small fraction was in phase S. TNF treatment decreased the amount of 
GO/Gl-phase cells and the amount of cells at S phase increased, ^"ig. 3.22b). Same 
observation could be made for cells treated with fixed-temperature hyperthermia ffig. 
3.22c). A drastic decrease in the amount of G0/G1 phase was observed when TNF-a and 
heat was combined OFig. 3.22d-f) especially when TNF-a was administered 3 hours or 
longer before heat. The amount of S-phase cells, as well as the necrotic or apoptotic cells 
also increased. The amount of GO/Gl-phase cells gradually increased as the TNF 
administration time was delayed ffig. 3.22g-j). The latter the TNF was administered, the 
higher level the G0/G1 phase peak reached, indicating the more cells were at this phase of 
cell cycle; however the change in S-phase cells must be seen with a graph. 
The percentage of cells at different phases of the cell cycle were calculated and 
presented in Fig. 3.23. Figure 3.23a showed the fraction of cells at G0/G1 phase after 
treated with TNF + fixed-temperature hyperthermia with different times of TNF 
administration. The amount of GO/Gl-phase cells after all treatments, regardless when 
rhTNF-a was administered, were significantly different from the control (p<0.05 for control 
with t=3 hours, p<0.005 for other). Especially low amount of G0/G1 cells were seen after 
treatments with TNF added 3 or 4 hours before fixed-temperature hyperthermia. TNF 
treatment was found to produce significantly less G0/G1 cells than hyperthermia (p<0.005). 
The change of the amount of S-phase cells in relation to TNF administration time 
was shown in Fig. 3.23b. Percentage of S-phase cells was found to have increased after all 
treatments, regardless when TNF was administered. Highest amount of S-phase cells were 
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Fig. 3.22 Change of Distribution of EAT cells in Different cells cycle phases after 
TNF + Fixed-temperature hyperthermia treatment with Different rhTNF-a 
Administration Time. EAT cells were treated with TNF + fixed-temperature 
hyperthermia as described in Fig. 3.1a. Cells were harvested and analyzed using flow 
cytometer. (a) Control; (b) TNF treatment; (c ) Fixed-temperature hyperthermia treatment; 
(d) rhTNF-a administered 6 hours before heat; 
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Fig. 3.22 Change of Distribution of EAT cells in Different cells cycle phases after 
TNF + Fixed-temperature hyperthermia treatment with Different rhTNF-a 
Administration Time (continue), (e) rhTNF-a administered 4 hours before heat; (f) 
rhTNF-a administered 3 hours before heat; (g) rhTNF-a administered 2 hours before heat; 
(h) rhTNF-a administered 0 hours after heat; 
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Fig. 3.22 Change of Distribution of EAT cells in Different cells cycle phases after 
TNF + Fixed-temperature hyperthermia treatment with Different rhTNF-a 
Administration Time (continue), (i) rhTNF-a administered 3 hours after heat; (j) rhTNF-
a administered 6 hours after heat. 
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found for TNF + fixed-temperature hyperthermia treatments with t = -4 and -3 hours TNF 
administration times. The increases were found to be more than 20% as compared to the 
control, reaching at about 60% and 67%, respectively. 
The change ofthe amount ofG2/M phase was mild (F'ig. 3.23c). The percentage of 
cells in G2/M phase were in a range of 7% - 15%. TNF + fixed-temperature hyperthermia 
treatment with t = -4 and -3 hours were two exceptions. About 25% and 20% of G2fM-
phase cells were resulted. 
Percentage ofother were exceptionally high for cells treated with rhTNF-a 3 and 4 
hours before fixed-temperature hyperthermia ffig. 3.23d). All of the other treatments 
produced less than 15% of cells in this category. TNF + fixed-temperature hyperthermia 
treatment with t =-4 hour TNF administration time resulted in about 45%; whereas 
treatment with t = -3 hour TNF administration time resulted in about 65% ofother, showing 
that a tremendous amount of cells were killed via necrosis or apoptosis after these two 
treatments. 
Percentage of GO/Gl-phase cells was found to have decreased after TNF, fixed-
temperature hyperthermia, or combination of the two treatments; whereas the percentage of 
S-phase cells increased. This change was especially obvious when rhTNF-a was 
administered 3 or 4 hours before fixed-temperature hyperthermia. The amount of necrotic 
and/or apoptotic cells after these treatments were outstandingly high. Consistently, the 
relative growth and viability were found to be the lowest when rhTNF-a was administered 
4 hours before fixed-temperature hyperthermia. A relationship between the change of 
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Fig. 3.23 Percentage of EAT cells at Different Cell Cycle Phases after TNF + Fixed-
temperature Hyperthermia Treatment with Different rhTNF-a Administration Time. 
EAT cells were treated with TNF + fixed-temperature hyperthermia with different TNP 
administration time as described in Fig. 3.1a. Cells were harvested and analyzed using flow 
cytometer. (a) %G0/G1 phase; (b) %S phase; (c ) %G2M phase; (d) % Other. 
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distribution ofEAT cells in cell cycle with the effectiveness of this treatment is suggested. 
3.5.2 Different Times of TNF Administration and Distribution of HL-60 Cells in Cell 
Cycle: 
Distribution ofHL-60 cells in difFerent phases of cell cycle after TNF and/or fixed-
temperature hyperthermia treatment were shown in Fig. 3.24. Fig. 3.24a showed the 
distribution of untreated cells. A sharp peak was shown at round 420 units 0fFL2-area to 
represent GO/Gl-phase cells. The second peak at 780 units represented the G2M-phase 
cells. A tall G0/G1 peak indicated that a large portion of the untreated HL-60 cells should 
be in the G0/G1 phase. Only a small amount of cells were allocated between the two peaks, 
showing that only a small fraction of cells was at S phase. 
HL-60 cells treated with fixed-temperature hyperthermia showed a decrease in 
G0/G1 peak (Fig. 3.24c) indicating a decrease in fraction of cells at the resting phase by 
fixed-temperature hyperthermia. However, rhTNF-a did not seem to cause any decrease of 
GO/Gl-phase cell (Fig. 3.24b). On the other hand, the amount of S-phase cells did not 
seem to have changed. However, the percentage of GO/Gl-phase cells dropped suddenly 
when TNF treatment was combined with fixed-temperature hyperthermia, with TNF applied 
before fixed-temperature hyperthermia (Fig. 3.24d-f). The G0/G1 peaks ofTNF + fixed-
temperature hyperthermia treatments with t = -6，-4, -3 hours, were obviously lower than 
the other treatments. In addition, a little extra peak was shown before the G0/G1 peak in 
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Fig. 3.24 Change of Distribution of HL-60 cells in Different cells cycle phases after 
TNF + Fixed-temperature hyperthermia treatment with Different rhTNF-a 
Administration Time. HL-60 cells were treated with TNF + fixed-temperature 
hyperthermia as described in Fig. 3.4a. Cells were harvested and analyzed using flow 
cytometer. (a) Control; (b) TNF treatment; (c ) Fixed-temperature hyperthermia treatment; 
(d) rhTNF-a administered 6 hours before heat; 
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Fig. 3.24 Change of Distribution of HL-60 cells in Different cells cycle phases after 
TNF + Fixed-temperature hyperthermia treatment with Different rhTNF-a 
Administration Time (continue), (e) rhTNF-a administered 4 hours before heat; (f) 
rhTNF-a administered 3 hours before heat; (g) rhTNF-a administered 2 hours before heat; 
(h) rhTNF-a administered 0 hours after heat; 
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Fig. 3.24 Change of Distribution of HL-60 cells in Different cells cycle phases after 
TNF + Fixed-temperature hyperthermia treatment with Different rhTNF-a 
Administration Time (continue), (i) rhTNF-a administered 3 hours after heat; Q) rhTNF-
a administered 6 hours after heat. 
117 
each histogram of these treatments. These peaks represented the necrotic/apoptotic cells 
with fragmented DNA. Such peaks were only shown in these treatments. Moreover, the 
G2M peaks in treatments with t = -6 and -4 hours TNF administration time also decreased, 
indicating that less cells was dividing under these treatments. 
The G0/G1 peak started to go up again when TNF administration time was delayed 
to 2 hours before fixed-temperature hyperthermia ^"ig. 3.24g). Distribution ofcells in cell 
cycle after TNF + fixed-temperature hyperthermia with rhTNF-a administered after heat 
were very similar to the untreated cells OFig. 3.24h-j). 
The percentage ofHL-60 cells in different phases of cell cycle was calculated and 
plotted in Fig. 3.25. Figure 3.25a showed the amount of cells at G0/G1 phase. TNF + 
fixed-temperature hyperthermia treatment with t = -6, -4, and -3 hours TNF administration 
time all showed significant reduction of GO/Gl-phase cells. The lowest percentage of 
GO/Gl-phase cell was achieved by adding rhTNF-a before fixed-temperature hyperthermia. 
Higher percentage of GO/Gl-phase cells was obtained for treatments with delayed TNF 
administration time. 
Figure 3.25b showed the percentage of S-phase cells. TNF + fixed-temperature 
hyperthermia treatment with rhTNF-a added 4 hours before heat was found to involve the 
highest amount of S-phase cells. Over 45% of cells under this treatment was at S phase. 
About 45% of S-phase cells was also found for treatment with t = -3 hour TNF 
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Fig. 3.25 Percentage ofHL-60 cells at Different Cell Cycle Phases after TNF + Fixed-
temperature Hyperthermia Treatment with Different rhTNF-a Administration Time. 
HL-60 cells were treated with TNF + fixed-temperature hyperthermia with different TNF 
administration time as described in Fig. 3.4a. Cells were harvested and analyzed using flow 
cytometer. (a) %G0/G1 phase; (b) %S phase; (c ) VoG2M phase; (d) % Other. 
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The change ofpercentage of G2M-phase cells was slight (¥{g. 3.25c); however, the 
percentage of cells at this phase had generally increased and were significantly higher than 
the untreated cells, regardless when rhTNF-a was administered. 
The percentage of other for treatments with t = -6 and -4 hours TNF administration 
time were outstandingly higher than the other, indicating that a large portion of necrotic or 
apoptotic cells existed. Over 40% of necrotic or apoptotic cells was found. Treatment with 
t = -3 hour TNF administration time also produced a significantly higher percentage of 
other, indicating that this treatment had also killed HL-60 effectively. The result was 
consistent with the findings of the previous experiments. 
For both EAT and HL-60 cells, a decrease in the percentage of GO/Gl-phase cell 
and an increase of S-phase cells were found. Highest changes were found in treatment with 
t = -4 hour TNF administration time. This result correlated well with the decrease of 
relative growth and viability of the two cell lines after TNF + fixed-temperature 
hyperthermia treatment with different TNF administration time. A correlation between the 
two was suggested. 
3.5.3 Shift ofCeIls Cycle after TNF Treatment: 
To investigate whether synergism is involved in the shift of cell cycle by TNF, cells 
were collected at different time points after TNF administration. 
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3 5.3.1 Response ofEhrlich Ascites Tumor ^ A D Cells: 
The shift ofcell cycle distribution is shown in Fig. 3.26. Cells collected immediately 
after TNF treatment were indifferent from the control ^ ¾ . 3.26a). The G0/G1 obviously 
dropped after 2-hour incubation with rhTNF-a, and the percentage of S-phase cells 
increased ^'ig. 3.26b). The G0/G1 peak continued to lower OFig- 3.26c-d) with the increase 
of S phase cells. At 6 hours, the G0/G1 peak rose again. The percentage of ceUs at 
different phases were calculated and shown in Fig. 3.27. The percentage of S-phase cells 
was found to increase with time, and peaked at 3 hours after TNF treatment. The 
percentage started to retum to normal after that time but still remained at a high level after 
4 hours. On the other hand, the percentage of GO/Gl-phase cells started to drop after TNF 
administration and remained at the lowest level between the third and fourth hours of 
incubation. It then rose back to about 28.1% at the sixth hour. Continuing increase of 
VoG2M was observed. The change of percentage of cells with DNA content other than 
these categories was constant, indicating that no DNA fragmentation occurred at such an 
early stage of treatment. 
3.5.3.2 Response ofHuman leukemia fflDL-60) Cells: 
Tall, sharp peak of G0/G1 phase was obtained for HL-60 cells collected at 0 hour 
after TNF treatment ^"ig. 3.28a). Drop of the G0/G1 peak was observed for cells collected 
at the second, third, and fourth hours of incubation with rhTNF-a (Fig. 3.28c-e), and a 
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Fig. 3.28 Shift of Distribution of HL-60 cells in Cell Cycle Phases after TNF 
Treatment. HL-60 cells at 5.0xl0^ cells/ml, after seeded for 20 hours at 37�C were treated 
with lOOng/ml of rhTNF-a. Cells were then collected at different time interval and 
analyzed using flow cytometer. (a) Control; ¢ ) Cell collected at 0 hour; (c ) Cells collected 
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Fig. 3.29 Shift ofDistribution of HL-60 cells in Different Cell Cycle phases after TNF 
Treatment. The protocol was similar to that described in Figure 3.28. 
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change of percentage of S-phase cells appeared to be slight, and might not be noticed until 
they were calculated and plotted in Fig. 3.29. The percentage of S-phase cells was found to 
increase with incubation time and peaked at the fourth hour of incubation with TNF. The 
increase was over 10%. The percentage of S-phase cells dropped back to 30% of whole 
cell population after 6 hours of incubation. The percentage of GO/Gl-phase cells was found 
to be decreasing with time. Consistently, it dropped to the lowest point at fourth hour of 
incubation and started to rise up again to its normal state (about 50%). The decrease was 
more than 15%. A slight increase of G2M-phase cells was found. The change of 
percentage of cells with DNA content other than these categories was negligible, showing 
that no necrosis or apoptosis occurred at that stage. 
The above experiments confirmed that rhTNF-a could cause an increase of S-phase 
cells. The percentage of S-phase cells was found to be highest when the cells were 
incubated with rhTNF-a for 3-4 hours. This could serve as a ground for applying fixed-
temperature hyperthermia 3-4 hours after TNF treatment. This might also be an explanation 
for the enhancement of the effectiveness between the two individual anti-tumor treatments. 
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3.6 Effectiveness ofTreatments in vivo: 
Combined treatments with TNF and hyperthermia was found to be effective in vitro, 
especially with TNF + fixed-temperature hyperthermia in the above sections. Their 
effectiveness were then tested using animal model. The effectiveness of TNF, step-down 
hyperthermia, fixed-temperature hyperthermia, and their combinations in vivo were 
examined in this section. The probable existence of synergism between TNF and heat were 
also investigated. 
3.6.1 Dose-dependent Response: 
The effect of rhTNF-a on the relative growth of EAT cells in vivo was shown in 
Fig. 3.30. The amount of EAT cells collected from the abdominal cavity of BALB/c mice 
was found to be decreased with increasing rhTNF-a dosage. For those EAT-bearing mice 
injected with 2^ig of rhTNF-a per injection, the amount of EAT cells collected was only 
30% of untreated cells. The result showed that the response was dose-dependent. The 
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Fig. 3.30 Dose-response Curve of rhTNF-a on EAT ceIIs in vivo. BALB/c mice were 
injected with l.OxlO^ EAT cells at Day 0，and on Day 2，4，and 6, the mice were injected 
with different dosages of rhTNF-a. Cells were harvested on Day 7. Viable cells were 
counted by trypan blue exclusion method. 
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3.6.2 Change of Body Temperature During Hyperthermia: 
Whole body hyperthermia treatment in vivo was done by heating the mice, which 
were trapped inside a tube, in a waterbath preheated to 38.5�C or 37.5°C. The body 
temperature ofthe animal would obviously be different from the outside environment. To 
monitor the real heat dosage applied to the EAT cells, the body temperature of the animal 
during the two hyperthermia treatments had to be determined. 
Figure 3.31 showed the change ofbody temperature during hyperthermia. The body 
temperature gradually increased and after 30 minutes, it reached at 39.2°C. In the case of 
fixed-temperature hyperthermia, the mouse was continued to be heated at 38.5"C for 
another 30 minutes. The rate of increase in body temperature seemed to have reached at a 
plateau at that stage. The body temperature fiirther increased for only 0.2°C in the next 30 
minutes. The final body temperature of the mouse was 39.4°C 
In case of step-down hyperthermia, the temperature of the water bath was switched 
to 37.5"C after 30 minutes. The body temperature of the mouse started to drop. After 30 
minutes, the body temperature decreased to 38.7°C. 
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Fig. 3.31 Change of Body Temperature of BALB/c mice During Hyperthermia 
BALB/c mice were anesthetized and trapped inside the Falcon tube as described in Chapter 
2 and a probe was inserted into their rectum to test their body temperature change during 
fixed-temperature hyperthermia or step-down hyperthermia. The mice were heated at 
38.5°C for 1 hour for fixed-temperature hyperthermia treatment and 38.5�C for 30 minutes 
and then at 37.5"C for 30 minutes in the case ofstep-down hyperthrmia. 
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3.6.3 Comparison ofEffectiveness ofVarious Treatments in vivo: 
Various treatments were tested on BALB/c mice, including TNF; fixed-temperature 
hyperthermia, which was done by heating the mice at 38.5�C for 1 hour; and step-down 
hyperthermia, which was done by heating at 38.5�C for 30 minutes and then at 37.5�C for 
another 30 minutes; and combination ofTNF and heat. Confinement inside a tube might 
induce stress to the mice and that might affect the result of the treatment, so a control was 
done by confining the mice inside the tube as described before and putting them in a 
waterbath preheated at room temperature (25T), so that the effect ofstress imposed to the 
mice by the confinement could be examined. The result showed that the difference between 
the untreated group and the group heated at room temperature was not significant (p>0.05) 
^ ig 3.32)，confirming that the stress of the mice had no effect on the treatments result. 
Neither fixed-temperature hyperthermia nor step-down hyperthermia alone could lower the 
relative growth of EAT inside the mice. Treatment of rhTNF-a was quite effective. It 
suppressed the growth of EAT cells to less than 40%. When TNF was combined with 
fixed-temperature hyperthermia, the effectiveness was greatly enhanced. TNF prior to 
fixed-temperature hyperthermia was found to be the most effective treatment, the amount 
ofEAT cells was suppressed to 14% of control. The amount ofEAT cells was suppressed 
to 29.5% after treated with TNF + step-down hyperthermia treatment. Both of these 
treatments showed significantly lower relative growth than the untreated cells (p<0.005); 
however, the difference between the relative growth resulted from sole TNF treatment and 
that resulted from TNF + step-down hyperthermia was not significant 
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Fig. 3.32 Relative Growth and Viability of EAT cells treated with rhTNF-a and 
Hyperthermia in vivo. EAT-bearing BALB/c mice (inoculated on Day 0) were treated 
with different treatments on Day 2，4，6. Control = injected with PBS; Heat 25C = heat at 
room temperature; TNF = TNF treatment; Hyper = Fixed-temperature hyperthermia; SDH 
=step-down hyperthermia; TNF/Hyper = TNF prior to fixed-temperature hyperthermia; 
TNF/SDH = TNF prior to step-down hyperthermia; HyperATNF = fixed-temperature 
hyperthermia prior to TNF treatment. EAT cells were harvested on Day 7. Viable cells 
were counted by trypan blue exclusion method. 
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(p>0.05). Relative growth resulted from TNF + fixed-temperature hyperthermia was 
significantly lower than sole TNF treatment (p<0.05). However, when the mice were 
heated before TNF treatment, the effectiveness was reduced. Over 50% of control of ceUs 
could be harvested from the animals after treatment. The amount of cells was higher than 
that harvested from mice treated with rhTNF-a only. The result suggested that heat might 
have protected the EAT cells from the effect ofTNF when heat was applied before rhTNF-
a. More dead cells could be harvested from mice treated with TNF + fixed-temperature 
hyperthermia and TNF + step-down hyperthermia. The viabilities were found to be 71.3% 
and 79.9%, respectively. However, this was not reliable indicator since dead cells inside the 
mice's body might be eliminated by the hosts' immune systems. 
3.6.4 Synergistic Effect Between rhTNF-a and Hyperthermia in vivo in Suppression 
of Tumor Growth: 
The existence of synergism between rhTNF-a and heat was under investigation. As 
indicated in Table 3.3，the expected percentage of control, with the assumption that only 
additive effect was involved, were calculated to be 33.45% and 48.90% for TNF + fixed-
temperature hyperthermia and TNF + step-down hyperthermia treatment, respectively. 
However, the experiments showed that only 14.03% and 29.49% of control was left after 
TNF + fixed-temperature hyperthermia and TNF + step-down hyperthermia treatment. The 
nearly 20% difference between the calculated result and the experimental result strongly 
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suggested synergism between rhTNF-a and fixed-temperature hyperthermia, and rhTNF-a 
and step-down hyperthermia. 
The in vivo experiment concluded that, in consistent with the in vitro experiments, 
TNF + fixed-temperature hyperthermia was the most effective combined treatment. The 
result also concluded that rhTNF-a must be added before heat in order to achieve maximum 
efFect, and synergism between rhTNF-a and hyperthermia was confirmed by both in vitro 




































































































































































Chapter Four: Discussion 
Optimal sequence of combined treatments with rhTNF-a and hyperthermia were 
determined, and the effectiveness of these treatments were compared in this study. The 
results were presented in two forms: the relative growth and viability. Relative growth was 
indeed a ratio of the cell density resulted after treatments to the cell density resulted without 
any treatment; and thus it reflected the difference between the cell density after treatment 
and the cell density that should be resulted if no treatment was done. The relative growth 
would hence be an indicator for the cytostaticity ofthe treatments. Viability, on the other 
hand, was the survival rate in the total cell population; and thus reflected the cytotoxicity of 
treatments. TNF + fixed-temperature hyperthermia and TNF + three different kinds ofstep-
down hyperthermia were examined. Step-down hyperthermia 1 and step-down 
hyperthermia 2 represented step-down hyperthermia with short-heating duration, while 
step-down hyperthermia represented step-down hyperthermia with long-heating duration. 
Step-down hyperthermia 1 and 2 allowed the comparison ofefFectiveness ofthe two types 
ofhyperthermia treatments with the same heating duration. In the sequence determination 
experiment, the sequence of step-down hyperthermia 2 was determined as a representative 
for step-down hyperthermia with short-heating duration. Both murine Ehrlich Ascites 
Tumor ^ A T ) cells and human leukemia HL-60 cells were tested. 
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4.1 Optimal Sequence of Treatments: 
Not much attempt was made to find out the exact optimal sequence of treatment 
between rhTNF-a and hyperthermia. A study done by Tomasovic et, al (1989) showed 
that TNF treatment preceding fixed-temperature hyperthermia by 1-4 hours enhanced killing 
and that effect was reduced or eliminated ifTNF treatment followed heating by 1-4 hours. 
However the sequence for TNF + step-down hyperthermia treatments were not determined. 
The finding of this study showed that rhTNF-a applied before hyperthermia, 
regardless fixed-temperature or step-down, achieved higher cytostaticity and cytotoxicity. 
Relative growth and viability generally rose as TNF administration time was delayed in all 
combined treatments (Fig. 3.1 - 3.6). This proved that the later the TNF administration 
time, the less severe the treatments were. Four hours before initiation ofheat was found to 
be the best TNF administration time for both TNF + fixed-temperature, and TNF + step-
down hyperthermia 3 treatments for both EAT and HL-60 cells ^Fig. 3.1，3.3，3.4’ 3.6). 
Recombinant human TNF-a was best administered at 6 hours before heat for TNF + step-
down hyperthermia 2 treatment for both EAT and HL-60 cells ^"ig. 3.2, 3.5). These results 
agreed with that found by Tomasovic et. al. (1989). Three hours before hyperthermia could 
still be very effective sometimes, and 6 hours before hyperthermia in some cases might not 
be too early to achieve effective cytostaticity and cytotoxicity. This observation showed that 
the best TNF administration time could sometimes fluctuate, but it would be around 4 hours 
before heat. Similar to the result obtained by Tomasovic et. al. (1989)，a time range was 
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found as the better TNF administration time; unlike the result obtained by them, the time 
range was earlier for EAT cells and HL-60 cells than that found in their experiments in 
which murine L929 cells were used. But one thing can be confirmed: A relatively long 
interval between TNF treatment and hyperthermia treatment seemed to be necessary. It 
seems that rhTNF-a required a certain period of time in order to take effect in the tumor 
cells and sensitize the cells to heat. The sensitizing period was necessary for both fixed-
temperature hyperthermia as well as step-down hyperthermia. This sensitizing period was 
especially important for TNF + step-down hyperthermia 2 treatment, since a period less 
than 4 hours would result in elimination of synergistic cytostatic effect on EAT cells, and no 
cytotoxic effect would be resulted for HL-60 cells with rhTNF-a added later than t = -6 
hour. 
Reversed-sequence treatment, that is hyperthermia treatment prior to TNF 
treatment, was found to cause the synergistic effect between rhTNF-a and hyperthermia to 
vanish in most cases. Especially for HL-60 cells, synergism in cytostatic and cytotoxic 
effect were both eliminated when hyperthermia was applied before rhTNF-a. As in the case 
of TNF + fixed-temperature hyperthermia on HL-60 and TNF + step-down hyperthermia 3 
treatment on EAT cells, only additive effect was found between the two individual 
treatments in exerting their cytostaticity. In some cases, applying rhTNF-a could conceal 
the effect of rhTNF-a, as in the case of TNF + step-down hyperthermia 3 treatment on HL-
60. Both cytostaticity and cytotoxicity were found to be the same as those resulted from 
step-down hyperthermia 3 treatment only. Addition of rhTNF-a was useless in enhancing 
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the effectiveness of the treatments when it was added after step-down hyperthermia 3. In 
the worst cases, reversed-sequence treatment could be protective. Applying heat before 
rhTNF-a could result in less cytostaticity and/or cytotoxicity than rhTNF-a alone. 
Elimination of rhTNF-a effect or protection against rhTNF-a by heat might be due to the 
production of protective agents such as heat shock proteins and superoxide dismutase 
(SOD). Heat shock protein 25 (human hsp27) and 70 (hsp25 and hsp70) level inside tumor 
cells were found to increase after fixed-temperature hyperthermia and step-down 
hyperthermia 3 treatments (Klostergaard et. al, 1996). Overexpression of hsp27, hsp70 
and hsp90 were found to confer resistance to heat, as well as to rhTNF-a. ^lichards et. al., 
1996; Gabai et. al, 1994; Jaattela et. al, 1992; Jaattela et al., 1989). TNF cytotoxicity 
partly involves the production of reactive oxidative species, but heat shock prevented 
oxidative injury (Polla et. aL, 1996). The relationship between the sequence oftreatment 
and the level of SOD expression has not been determined yet. But since the overexpression 
of the manganese-containing superoxide dismutase (MnSOD) confers resistance to the 
cytotoxicity ofboth rhTNF-a and hyperthermia OLi and Oberley, 1997), the expression of 
SOD might play a role in the resistance to the reversed-sequence treatment. This might be 
ofinterest to investigate. 
Surprisingly, the reversed-sequence treatments of TNF + fixed-temperature 
hyperthermia and TNF + step-down hyperthermia 3 were still very effective against EAT 
cells. Regardless when rhTNF-a was added, TNF + fixed-temperature hyperthermia was 
more effective in suppressing the growth of EAT cells than single treatments. The 
141 
cytotoxicity of reversed-sequence TNF + step-down hyperthermia 3 treatments were more 
severe than the added effect of the two single treatments. These observations might be due 
to the high sensitivity ofEAT cells to TNF + hyperthermia treatments. To EAT cells, TNF 
+ fixed-temperature hyperthermia and TNF + step-down hyperthermia 3 were so severe that 
even when the treatment sequences were reversed, the production of protective agents 
could not protect the cells from the damages induced by rhTNF-a and hyperthermia 
together. On the other hand, since step-down hyperthermia 2 was much less severe, the 
reverse of treatment sequence resulted in protection by step-down hyperthermia 2 from the 
cytostaticity of rhTNF-a and total elimination of cytotoxicity. Nevertheless, heat 
treatments prior to TNF treatment were less effective and thus is less desirable. Adding 
rhTNF-a 4 hours or 6 hours before hyperthermia were still the best sequence oftreatments 
found in this study. 
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4.2 Comparison ofVarious Treatments: 
Using the optimal treatment sequences, the effectiveness of various treatments, as 
well as their harmfulness on normal cells, were compared. TNF + fixed-temperature 
hyperthermia was found to be the most effective treatment for both EAT and HL-60 cells, 
and step-down hyperthermia treatment was effective only when the heating time was 
prolonged (that is TNF + step-down hyperthermia 3). TNF + heating at 43�C for 1 hour did 
not produce much effect, and TNF + heating at 40°C for 24 hours produced almost the 
same effect as TNF + step-down hyperthermia 3’ indicating that heating at 40�C for 24 
hours contributed the most to the effectiveness ofTNF + step-down hyperthermia 3. This 
result was different from that obtained by Klostergaard et. al, (1996). By using L929 
EMT-6, HT-15, and DLD-1 cells, they found that TNF + step-down hyperthermia with 
43°C for 1 hour and 40�C for 24 hours was the most effective treatment and was more 
effective than TNP + fixed-temperature hyperthermia. The contradiction might be due to 
the differences in tumor cells used, the sequence oftreatments used and the heating duration 
for the fixed-temperature hyperthermia. The sequence oftreatments they used was applying 
rhTNF-a immediately prior to the initiation of hyperthermia. Referring to the result 
obtained in this present study, both the cytostaticity and cytotoxicity of TNF + step-down 
hyperthermia 3 were stronger than those ofTNF + fixed-temperature hyperthermia on EAT 
cells, showing that the sequence of treatments used can affect the result in the comparison 
of effectiveness，and the use ofoptimal sequence oftreatment in the comparison ofvarious 
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treatments is critical. The heating time of fixed-temperature hyperthermia treatment was 
also different. Heating at 43�C lasted for at most one hour in the experiments done by 
Klostergaard et. al. (1996). Combined treatment with rhTNF-a and heating at 43�C for 1 
hour was shown in this study to be ineffective. But fixed-temperature hyperthermia for 3 
hours made a big difference. TNF + fixed-temperature hyperthermia for 3 hours was the 
most effective treatment found in this study. 
Combined treatment with TNF + step-down hyperthermia 2 was found to produce a 
similar effect as TNF + step-down hyperthermia 3 on HL-60 cells. The result suggested 
that one extra hour at 43�C could replace the prolonged heating at 40°C for 24 hours. 
When the combined treatments with rhTNF-a and fixed-temperature hyperthermia or step-
down hyperthermia with fixed heating period were compared, TNF + fixed-temperature 
hyperthermia was clearly the best combined treatment for both cell lines. 
The growth suppression effect in most cases started before the cytotoxic effect’ and 
was stronger than the cytotoxicity. The result showed that the treatments first tried to stop 
the tumor cells from growing, and then started to kill the existing cells. Apoptosis started 
to occur first in the case ofTNF + fixed-temperature hyperthermia on HL-60. TNF + step-
down hyperthermia 2 on HL-60 was an exception, which did not have strong effect on the 
cells. The cytostatic effect did not start until after the treatment. Nevertheless, the 
cytostaticity was stronger than the cytotoxicity. The cytostaticity of TNF + step-down 
hyperthermia 2 on EAT cells only lasted for 2 hours. Cytotoxic effect of TNF + fixed-
temperature hyperthermia on HL-60 also lasted for only 18 hours. The cells began to 
proliferate after that time. The effect of other treatments persisted over 24 hours. The 
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responses of the cells to these treatments would allow the design of course oftreatment on 
patients. For TNF + step-down hyperthermia 2, the second treatment application should be 
done in a short time. Since the effect of treatment only lasted for 2 hours, if the second 
application of treatment was delayed to after 24 hours, the tumor cells would have grown 
back to a high cell density as before treatment. The treatment done would have been 
wasted if that was the case. 
Percentage ofrelative growth and viability ofthe treatments obtained from the time-
course experiments varied from the comparison of effectiveness experiment. Lower relative 
growth and viability seemed to be obtained from TNF + step-down hyperthermia 3 than 
TNF + fixed-temperature hyperthermia. This discrepancy might be due to slight variation of 
experimental condition. Time-course experiment ofTNF + fixed-temperature hyperthermia 
treatment was not done at the same time as that of TNF + step-down hyperthermia 3. 
Variation such as cell growth condition and temperature fluctuation ofthe incubators could 
all make a big difference in the relative growth and viability resulted. All the experiments in 
this study were done by seeding the cells for 20 hours before treatments. The cell 
concentration after this pre-treatment incubation varied from 4xl0^ ceUs/ml to 7.8xl0^ 
cells/ml for EAT cells, and 6.3xl0^ cells/ml to 1.2xl0^ cells/ml for HL-60 cells (result not 
shown). This pre-treatment incubation was necessary since the cells freshly seeded on plate 
were more resistant to treatments. This might be because cells in fresh medium usually 
undergo a lag phase, at which the cells are more resistant to treatments. To mimic the 
condition inside a patient's body, the cells had to be seeded on plate for a certain period of 
time so that the cells would be actively growing. The variation in the cells density before 
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treatments could affect the outcome if the experiments were done in different times. Hence, 
in order to compare the effectiveness of these treatments, same batch of cells seeded at the 
same time had to be used for comparison, as did in this study. 
As mentioned before, apoptosis was involved in the killing mechanism of TNF + 
fixed-temperature hyperthermia on HL-60 cells, and it occurred at early stage after the 
treatment. Apoptosis was also found for this combined treatment against L929 and EMT-6 
cells (Tomasovic et. al., 1994). Indeed, both TNF treatment and fixed-temperature 
hyperthermia were found to be able to cause apoptosis in various tumor cell lines 
(Yonezawa et, al, 1996; Moroi et. cd., 1996; Fairbaim et. al., 1995; Sakaguchi et. al., 
1995; Bellomo et. aL, 1992). Mild hyperthermia is known to enhance apoptosis in tumor 
(Harmon et. al., 1990; Harmon et. al., 1989; Allan and Harmon, 1986) but whether step-
down hyperthermia could generate apoptosis is not yet known. The two step-down 
hyperthermia were found to involve mainly necrosis in this study. But the induction of 
apoptosis is cell-type dependent and is also depended on the accumulation ofhsp (Gabai et. 
al, 1995). 
In this study, DNA electrophoresis was done to find out if fragmented DNA are 
present in the cell culture after treatments. One way to distinguish apoptotic cells from 
necrotic cells is by the presence of nucleosomal-length DNA fragments (Gerschenson and 
Rotello, 1992). Apoptosis can cause cleavage of DNA at linker regions between 
nucleosomes, whereas the DNA cleavage in necrosis is random. As a result, 180-200, or its 
multiple, base pair fragments would be shown by agarose gel DNA electrophoresis. Other 
than this, microscopy can also be used to find out the presence of apoptosis. The main 
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morphological characteristic of apoptosis are nuclear fragmentation and ceUular breakdown 
in apoptotic vesicles. Blebs forms on membrane of apoptotic cells could be seen under 
phase contrast microscopy (Allan and Harmon, 1986). 
Knowing apoptosis occurred after TNF + fixed-temperature hyperthermia treatment 
allows the investigation on the killing mechanism ofthis treatment easier. Changes of the 
components of the apoptosis pathway can be investigated, such as caspases, and other 
Interleukin Converting Enzyme (ICE)-related proteases, and arachidonic acid. Any 
enhancement in the production or activation of these substances are still awaited to be 
found out. 
Other than being the most cytostatic and cytotoxic treatment, TNF + fixed-
temperature hyperthermia also produced the strongest synergistic effect. The huge 
enhancement in the effectiveness strongly suggested synergism between rhTNF-a and 
hyperthermia. The existence of synergism between the two individual treatments in the 
combined treatments was determined by first calculating the expected additive effect with 
the assumption that the enhanced effect was due to the addition ofeffects oftwo individual 
treatments. Hence the additive cytostaticity of TNF + fixed-temperature hyperthermia on 
EAT cells would be 91.71% of the 79% that was first suppressed by rhTNF-a. As a result, 
the expected additive effect would be 79% times 91.71%. Both experimental relative 
growth and viability ofEAT ceUs after TNF + fixed-temperature hyperthermia treatment 
were much lower than these calculated values. Same result was observed for HL-60 cells. 
The difference between the experimental results and expected values were greatest for TNF 
+ fixed-temperature hyperthermia treatment among the three combined treatments. 
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Synergism was not very obvious for TNF + step-down hyperthermia 2 and TNF + step-
down hyperthermia 3 treatments. More than additive effect was found for TNF + step-
down hyperthermia 2 treatment except for the cytotoxic effect on EAT cells. Similarly, no 
synergistic effect was found for TNF + step-down hyperthermia 3 treatment except for the 
cytotoxic effect on EAT cells. The existence of synergism for TNF + step-down 
hyperthermia 2 and TNF + step-down hyperthermia 3 treatments were not convincing. 
To decide whether a treatment is favorable in cancer treatment, the treatment's 
effect on normal cell must also be taken into consideration. Human Coronary Artery 
Endothelial Cells ^ICAEC) were used for testing in this study since this cell type is very 
sensitive to stress. Prolonged heat treatment, TNF + step-down hyperthermia 3，was very 
undesirable. HCAEC cells could tolerate short-duration heating, TNF + step-down 
hyperthermia 2, and no harmful effect was found for TNF + fixed-temperature hyperthermia 
treatment. Fixed-temperature hyperthermia seemed to have stimulated the growth of 
HCAEC cells. A similar result was also obtained for another normal cell line, a human lung 
fibroblast WI-38. The relative growth was also higher than untreated cells after treated 
with fixed-temperature hyperthermia and TNF + fixed-temperature hyperthermia (result not 
shown). The reason for that is unknown. 
In conclusion, with the highest effectiveness against both EAT and HL-60 cells, and 
absence ofharmful effect on normal cells, TNF + fixed-temperature hyperthermia was found 
to be the most favorable combined treatment ofTNP + hyperthermia in vitro. 
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4.3 Distribution of Cells in Cell Cycle Phases: 
This study found both the rhTNF-a and fixed-temperature hyperthermia could 
stimulate a decrease of percentage of GO/Gl-phase cells and an increase ofpercentage ofS-
phase cells. Combined treatment of the two, regardless when rhTNF-a was administered, 
could all lead to a decrease of percentage of GO/Gl-phase cells and an increase of 
percentage of S-phase cells. The change were most obvious for treatments with rhTNF-a 
added 6 hours, 4 hours, and 3 hours before heat, indicating strongest stimulation for these 
sequences of treatment. Change in percentage of G2M-phase was little. Increase of 
percentage of S-phase cells might mean more cell division, however, the result ofprevious 
experiments showed that the growth of cells were severely suppressed. Another support for 
the absence of cells division was the little increase in percentage of G2M-phase cells. The 
result showed that a large portion of cells did not pass to the G2M phase. There are 2 
possibilities speculated for the fate of the cells: the large decrease ofpercentage ofGO/Gl-
phase cells and relatively small increase in percentage of S-phase cells might be due to the 
death of G0/G1 cells; or the G0/G1 cells were stimulated to go to S phase and the cells 
were killed at the S phase. The former explanation is not supported by Gabai et. al. (1994， 
1995) and Rice et. al (1986), who claimed that stationary cells were more resistant to 
necrosis and apoptosis induced by heat. On the contrary, the second explanation would be 
more probable since TNF-a was found to be able to stimulate the increase ofpercentage of 
S-phase cells (Shih and Stutman, 1996)，and cells were more sensitive to heat at S phase, 
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probably due to aberrant DNA replication (Read et. al., 1983; Bhuyan, 1979; Dewey et. 
cd., 1978; Sapareto et. aL, 1978; Westra and Dewey, 1971). Therefore, a combination of 
the two individual treatments would stimulate more cells to go to S phase and then heat 
could kill the tumor cells at that phase. This argument is also supported by the result that 
shift in distribution of cells in cell cycle phases shifted after treated with rhTNF-a in this 
study. Recombinant human TNF-a was found to increase the percentage of S phase cells 
while lowering the percentage of GO/Gl-phase cells with time. A slight increase of 
percentage of G2M-phase cells after TNF + fixed-temperature hyperthermia treatment was 
observed for all TNF administration time, and it might be because some cells had escaped 
the cytotoxic effect and proceeded to G2M phase. The percentage ofother represented the 
amount ofnecrotic and apoptotic cells. This figure was extraordinarily high for treatments 
with t = -4 and -3 hours TNF administration time, indication that highest cell death were 
obtained from these sequence of treatments. These findings were consistent with the results 
obtained from the previous experiments. As mentioned before, this figure can represent the 
amount of necrotic and/or apoptotic cells. The presence of apoptosis has to be supported 
by DNA electrophoresis. Since EAT cells did not produce any apoptotic cells, the 
percentage solely represents the percentage ofnecrotic cells; whereas for HL-60 cells, part 
ofit might be apoptotic cells while the other might be necrotic cells. 
The effect ofrhTNF-a on cell cycle was also investigated and 3-4 hours after TNF 
administration were found to produce highest percentage of S-phase cells and lowest 
percentage of GO/Gl-phase cells. This phenomenon was also seen in WEH1 cells (Shih 
and Stutman, 1996). This finding can serve to explain why the sequence oftreatment with 
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rhTNF-a added 3-4 hours before fixed-temperature hyperthermia would be most cytotoxic. 
Since cells are more resistant to heat at G0/G1 phase and sensitive to heat at S phase, and 
3-4 hours after TNF administration produced highest percentage ofS-phase cells and lowest 
percentage of GO/Gl-phase cells, applying heat at this time would kill the largest amount 
cells. This also accounts for the greatest decrease of percentage of GO/Gl-phase cells, as 
well as the greatest increase of percentage of S-phase cells and percentage ofother in these 
sequences of treatment. 
The experiment of the effect of rhTNF-a also showed that after 6 hours of 
incubation with rhTNF-a, the percentage of G0/G1 and percentage of S started to retum to 
normal. This could explain why adding rhTNF-a 6 hours before heat did not result in 
synergistic effect. 
Percentage ofG2M-phase cells was found to increase, which might be an indication 
of cell division. However, results from previous experiments showed that TNF treatment 
did not result in more cell growth than control. Percentage of other in this experiment did 
not rise, indicating no cell death was obtained at that moment. Whether these newly grown 
cells ere killed in the later time of treatment, or these G2M-phase cells had never divided 
was not known. 
In conclusion, TNF + fixed-temperature hyperthermia with rhTNF-a added 3 or 4 
hours before heat were found to result in greatest decrease of percentage of GO/Gl-phase 
cells and highest percentage of S-phase cells. The change was probably due to the 
stimulation of shift of cell to S phase by rhTNF-a and then the killing of S-phase cells by 
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heat. The sensitization of cells to heat by TNF might account of the synergism between 
rhTNF-a and heat. 
Other than this alteration of cell cycle progression, rhTNF-a and heat may 
cooperate in other ways to enhance the effect of the treatment. One possibility is the 
deprivation of glucose due to the decrease of glucose uptake by rhTNF-a ^"ung et. aI., 
1995). This stress can sensitize the cells to heat ^Lank et. al., 1986; Calderwood et. al, 
1985; Gomes et. al., 1985). Besides, both rhTNF-a and hyperthermia can reduce glucose 
uptake, and this might contribute to the additive effect when the treatments were combined 
OFung and Lam, 1988). Enhancement in calcium influx can also make killing more efficient 
since both rhTNf-a and hyperthermia can induce increase of intranuclear and cytosolic free 
calcium concentration ^Cong et. al., 1997; Weider and Fox, 1995). Ca?+ influx might also 
sensitize the ceils to heat (Malhotra et. al., 1986; Wiegant et. al., 1987). Increase in 
intranuclear free calcium concentration may also induce apoptosis (Bellomo et. al., 1992). 
The inhibitory effects of hyperthermia on DNA, mRNA, and protein synthesis might 
enhance the sublethal or potentially lethal TNF damage by inhibition of TNF protective 
protein(s) production (Fung and Lam, 1988). Reactive oxidative species produced as a 
result ofTNF treatment are able to damage the DNA ofthe cells. With the inhibitory effect 
ofhyperthermia on DNA synthesis, the DNA damage might not be repaired, and thus give 
rise to cell death. Other effects ofTNF-a and hyperthermia such as decrease ofintracellular 
pH may also contribute to the enhancement ofcell killing. 
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4.4 In vivo Study: 
A lower temperature of hyperthermia (38.5"C) was used in this experiment firstly 
because this temperature was found to be high enough to produce a significant cell death or 
suppression in the combined treatment. Any unnecessary stress for the mice was not 
desired. In addition, high temperature (>42�C) whole body hyperthermia are not tolerated 
by some animals and often harm the normal cells (Matsuda et. al., 1997; Bull, 1983; 
Pettigrew et. al., 1974). Therefore, a lower temperature was used. 
The body temperature at such condition was measured to be 39.2"C, which was 
lower than that measured by Lui (1992) with the same temperature setting. The difference 
is probably due to anesthesia method. The mice were only briefly anaesthetized by ether in 
the experiments ofLui (1992). The mice regained mobility after a while, and movement 
would increase the body temperature of the animals. On the other hand, the mice were 
anaesthetized by pentobarbital for the whole experimental period in this present experiment. 
Lack of movement would lead to less heat generation. With the consideration that the 
insertion ofthe temperature probe into the animals' rectum would cause great pain to the 
animals, the mice were anaesthetized for the whole period oftime during experiment. 
Step-down hyperthermia in vivo was done by lowering the temperature of the 
waterbath to 37.5T after 30 minutes at 38.5"C. The body temperature ofthe mice dropped 
for 0.5�C only. Despite such a small change, the results of relative growth were 
significantly different from each other. 
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TNF + fixed-temperature hyperthermia again was found to be the most effective 
treatment in the in vivo study, and synergistic effect was observed. The result agreed with 
that ofthe in vitro study. TNF + step-down hyperthermia was less effective but synergism 
could still be observed. Heat treatment prior to TNF treatment was found to be 
undesirable, in consistent with the in vitro study, and protective effect by heat against the 
cytotoxic effect ofTNF was suggested. All ofthese findings were consistent with the result 
obtained in the in vitro study. 
Confinement within a tube was found to cause no stress-related influence on the 
result. However, heating the mice this way is suspected to be less effective than 
hyperthermia in vitro. Other than having a lower temperature, the heating was less constant 
since heating was not direct. The heating temperature would be affected by the 
environment, like air-flow and the outside temperature, and the movement ofthe mice. A 
bigger space between the mice and the heating surface would be resulted when the mice 
tried to stand up, and this space would make the heat transmission less efficient. 
As mentioned above, synergism was observed for both TNF + fixed-temperature 
hyperthermia and TNF + step-down hyperthermia treatments in vivo. Other than the 
mechanism ofsynergism discussed in the previous section, synergism in vivo might include 
the induction ofautologous tumor killing by y5 T-cells. Heat shock protein 70 production 
induced by hyperthermia was found to stimulate the proliferation ofthese T-cells clones and 
the tumor cells bearing the hsp70 markers would be recognized by the T cells and killed 
(Wei et. al., 1996). Since TNF-a is able to stimulate the proliferation of T cells and it 
works with other components ofthe immune system, the combined treatment ofTNF and 
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heat might be able to stimulate the immune system of the animals to eliminate the tumor 
cells more efficiently. In addition, hyperthermia is able to increase tumor oxygenation and 
blood flow (Song et. al., 1996). Increase ofblood flow can enhance the effectiveness of 
the combined treatment by faster transportation of TNF-a to the tumor cells. Increase of 
tumor oxygenation would also sensitize the cells to TNF-a. As hypoxic cells are more 
resistant to drugs, due to the increased level of stress proteins including hsp, thermal 
sensitization might be achieved by re-oxygenation of hypoxic cells. However, such 
hypothesis is still under much controversy (Kampinga et. al, 1997; Song, 1997; Dewey, 
1996). 
This study had demonstrated that TNF + fixed-temperature hyperthermia was the 
most effective combined treatment of TNF + hyperthermia in both in vitro and in vivo 
systems. Synergism between TNF-a and fixed-temperature hyperthermia was found to 
exist and it might be related to the shift in distribution of cells in cell cycle phase. Other 
mechanisms might be involved, and further investigation is necessary. 
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